EP3333177A1 - Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof - Google Patents
Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof Download PDFInfo
- Publication number
- EP3333177A1 EP3333177A1 EP15900056.1A EP15900056A EP3333177A1 EP 3333177 A1 EP3333177 A1 EP 3333177A1 EP 15900056 A EP15900056 A EP 15900056A EP 3333177 A1 EP3333177 A1 EP 3333177A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- gly
- formula
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 82
- 230000010100 anticoagulation Effects 0.000 title claims abstract description 17
- 230000000694 effects Effects 0.000 title abstract description 62
- 239000003146 anticoagulant agent Substances 0.000 title abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 230000000702 anti-platelet effect Effects 0.000 title abstract description 7
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims abstract description 24
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims abstract description 24
- 102000005962 receptors Human genes 0.000 claims abstract description 23
- 108020003175 receptors Proteins 0.000 claims abstract description 23
- 108090000190 Thrombin Proteins 0.000 claims abstract description 15
- 229960004072 thrombin Drugs 0.000 claims abstract description 15
- 230000008485 antagonism Effects 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 279
- 229920001184 polypeptide Polymers 0.000 claims description 272
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 272
- 208000007536 Thrombosis Diseases 0.000 claims description 69
- 239000003814 drug Substances 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 23
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003875 Wang resin Substances 0.000 claims description 11
- 108010016626 Dipeptides Proteins 0.000 claims description 9
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 7
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 6
- 210000004896 polypeptide structure Anatomy 0.000 claims description 6
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000000750 progressive effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 159000000021 acetate salts Chemical group 0.000 claims description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 26
- 230000002785 anti-thrombosis Effects 0.000 abstract description 13
- 238000000338 in vitro Methods 0.000 abstract description 10
- 230000002776 aggregation Effects 0.000 abstract description 7
- 238000004220 aggregation Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 4
- 125000005647 linker group Chemical group 0.000 abstract 2
- 229960003766 thrombin (human) Drugs 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 77
- 239000002504 physiological saline solution Substances 0.000 description 60
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 56
- 229960000610 enoxaparin Drugs 0.000 description 55
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 54
- 238000001990 intravenous administration Methods 0.000 description 42
- 238000012360 testing method Methods 0.000 description 40
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 32
- 239000008280 blood Substances 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 31
- 239000000243 solution Substances 0.000 description 30
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 26
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 26
- 230000023555 blood coagulation Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- 230000006870 function Effects 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 22
- 229960001500 bivalirudin Drugs 0.000 description 21
- 108010055460 bivalirudin Proteins 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 238000012423 maintenance Methods 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 210000001168 carotid artery common Anatomy 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 210000001105 femoral artery Anatomy 0.000 description 12
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 11
- NTUPOKHATNSWCY-JYJNAYRXSA-N Phe-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=CC=C1 NTUPOKHATNSWCY-JYJNAYRXSA-N 0.000 description 11
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 11
- 230000003042 antagnostic effect Effects 0.000 description 11
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 10
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 10
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 10
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 10
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 206010072564 Peripheral artery thrombosis Diseases 0.000 description 9
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000010253 intravenous injection Methods 0.000 description 9
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- JPWIMMUNWUKOAD-STQMWFEESA-N Gly-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN JPWIMMUNWUKOAD-STQMWFEESA-N 0.000 description 8
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 8
- -1 Val Chemical compound 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 108010084932 tryptophyl-proline Proteins 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 210000003191 femoral vein Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000004731 jugular vein Anatomy 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- 238000002627 tracheal intubation Methods 0.000 description 7
- 210000001631 vena cava inferior Anatomy 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000003194 forelimb Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 238000003149 assay kit Methods 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000004004 carotid artery internal Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 210000004623 platelet-rich plasma Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 4
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 4
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 4
- 206010047195 Vena cava thrombosis Diseases 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- 239000002985 plastic film Substances 0.000 description 4
- 229920006255 plastic film Polymers 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003188 neurobehavioral effect Effects 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 2
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- DWHCYDWXLJOFFO-UHFFFAOYSA-N 4-(5-phenylthiophen-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(C=2C=CC=CC=2)S1 DWHCYDWXLJOFFO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 229930182832 D-phenylalanine Natural products 0.000 description 2
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- LBDXVCBAJJNJNN-WHFBIAKZSA-N Gly-Ser-Cys Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O LBDXVCBAJJNJNN-WHFBIAKZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000000157 blood function Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 229960005153 enoxaparin sodium Drugs 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 208000021331 vascular occlusion disease Diseases 0.000 description 2
- SJVFAHZPLIXNDH-JOCHJYFZSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-JOCHJYFZSA-N 0.000 description 1
- MGHMWKZOLAAOTD-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-DEOSSOPVSA-N 0.000 description 1
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- UCARTONYOJORBQ-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-trityloxypropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 UCARTONYOJORBQ-UMSFTDKQSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- XJFPXLWGZWAWRQ-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O XJFPXLWGZWAWRQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 1
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- QSFJHIRIHOJRKS-ULQDDVLXSA-N Tyr-Leu-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QSFJHIRIHOJRKS-ULQDDVLXSA-N 0.000 description 1
- AVIQBBOOTZENLH-KKUMJFAQSA-N Tyr-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N AVIQBBOOTZENLH-KKUMJFAQSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
Definitions
- the present invention relates to the biomedical field, in particular to a multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism as well as a preparation method thereof and use thereof.
- Thrombosis is an early event during the occurrence of thrombotic diseases and runs through the development of the diseases. Platelet activation and activation of the blood coagulation system play an important role in the process of thrombosis, and are closely related to each other in vivo. Thrombin, which is produced when the blood coagulation system is activated, is a potent platelet activating factor to activate platelets, which in turn facilitates the blood coagulation process.
- the principle of the prevention and treatment of the thrombotic diseases is to improve the hypercoagulable state, to prevent thrombus extension and new thrombus formation, to dissolve thrombus and then to clear or rebuild the blood flow path, thereby preventing ischemia and necrosis of tissues.
- Methods for treating the thrombotic diseases include antithrombotic, thrombolytic, interventional and surgical therapies.
- the antithrombotic therapy includes antiplatelet and anticoagulant therapies, and it has been of concern as a foundation for the treatment of thrombotic diseases, especially cardiovascular diseases.
- Anticoagulant drugs prevent the blood coagulation process and thereby prevent thrombosis by acting on blood coagulation factors; antiplatelet drugs inhibit thrombosis by functions of inhibiting platelet adhesion, aggregation and release.
- clinically used thrombin inhibitors mainly include low molecular weight heparin and bivalirudin; and platelet GPIIb/IIIa receptor antagonists mainly include lamivudine, tirofiban, etc.
- An object of the present invention is to overcome the defects existing in the prior art and to provide a multi-target antagonistic compound which is capable of simultaneously targeting thrombin and platelet GPIIb/IIIa receptors.
- the present disclosure provides a multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism, said compound having a structure represented by Formula (1): A-L-B-L'-C Formula (1), wherein A and B are thrombin binding sites, C is a platelet GPIIb/IIIa receptor binding site, L is a first linker, and L' is a second linker.
- L' has a structure represented by Formula (2): ((Gly) n1 -(Ser) n2 ) n3 Formula (2), wherein n1 is 1, 2, 3 or 4; n2 is 0 or 1; and n3 is 0, 1, 2 or 3.
- L' has a structure represented by Formula (3): (Glu-Ala-Ala-Ala-Lys) n1 Formula (3), wherein n1 is 0, 1, 2 or 3.
- L' has a structure represented by Formula (4): (Arg-Val-Leu-Ala-Glu-Ala) n1 Formula (4), wherein n1 is 0, 1, 2 or 3.
- A has a structure represented by Formula (5): A1-A2-A3-A4 Formula (5), wherein A1 is D-Phe; A2 is Pro or Pip; A3 is Arg, Lys, Orn or Har; and A4 is Pro, D-Pro or Ser.
- B has a structure represented by Formula (6): B1-B2-B3-B4-B5 Formula (6), wherein B1 is a dipeptide consisting of any two acidic amino acids; B2 is Val, Leu, Ile, Nle or Phe; B3 is Hyp, Ser, Pro or an N-methyl amino acid; B4 is a dipeptide consisting of any two acidic amino acids; B5 is an amino acid selected from the group consisting of Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro, or B5 is a dipeptide comprising at least one amino acid selected from Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro.
- B1 is a dipeptide consisting of any two acidic amino acids
- B2 is Val, Leu, Ile, Nle or Phe
- B3 is Hyp, Ser, Pro or an N-methyl amino acid
- B4 is a dipeptide consisting of any two acidic amino acids
- C has a structure represented by Formula (7): Cys-Har-C1-Asp-Trp-Pro-C2 Formula (7), wherein C1 is Gly or Ser; C2 is Cys or a structure obtained by replacing -OH in Cys with -NH 2 ; and a disulfide bond is formed between two mercapto groups in the Formula (7).
- L has a structure represented by Formula (8): L1-L2-L3-L4-Gly-Asp-L5 Formula (8), wherein L1 is Gly, Ala, Val or Gly-Gly; L2 is Gly or Cys; L3 is Gly, Gly-Gly, Gly-Gly-Gly or a dextrorotatory amino acid; L4 is Asn or Gln; L5 is one selected from Phe, Tyr, a derivative in which a benzene ring of Phe is substituted, and a derivative in which a benzene ring of Tyr is substituted.
- Formula (8) wherein L1 is Gly, Ala, Val or Gly-Gly; L2 is Gly or Cys; L3 is Gly, Gly-Gly, Gly-Gly-Gly or a dextrorotatory amino acid; L4 is Asn or Gln; L5 is one selected from Phe, Tyr, a derivative in which a benzen
- A-L-B is selected from one of the polypeptide sequences shown in SEQ ID No. 1 to SEQ ID No. 3.
- said compound has a structure represented by Formula (9): X-A-L-B-L'-C-Y Formula (9), wherein X is one selected from hydrogen, one or two C1-C6 alkyl, one or two C2-C10 acyl, benzyloxycarbonyl and tert-butoxycarbonyl; Y is one selected from OH, C1-C6 alkoxy, an amino, and an amino substituted with one or two C1-C4 alkyl.
- Formula (9) X-A-L-B-L'-C-Y Formula (9), wherein X is one selected from hydrogen, one or two C1-C6 alkyl, one or two C2-C10 acyl, benzyloxycarbonyl and tert-butoxycarbonyl; Y is one selected from OH, C1-C6 alkoxy, an amino, and an amino substituted with one or two C1-C4 alkyl.
- said compound comprises a polypeptide sequence of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- said compound is selected from one of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- the present disclosure further provides a salt of the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism.
- said salt is an acetate salt of the compound or a trifluoroacetate salt of the compound.
- the present disclosure further provides a method for preparing the compound of the present disclosure, wherein the method comprises the steps of:
- the present disclosure also provides a pharmaceutical composition, wherein said pharmaceutical composition comprises the compound of the present disclosure or a salt of the compound of the present disclosure as an active ingredient.
- the dosage form of said pharmaceutical composition is an injection, a tablet, a capsule, a pill, a powder, a granule, a suspension or an emulsion.
- the present disclosure also provides use of the compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of peripheral arterial thrombosis, arterial and venous bypass thrombosis.
- the present disclosure also provides use of the compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of progressive ischemic stroke, in the manufacture of a medicament for the treatment of thrombosis in acute coronary syndromes, percutaneous coronary intervention, or therapy with a coronary stent in PCI, in the manufacture of a medicament for the prevention and treatment of acute pulmonary embolism, or in the manufacture of a medicament for the prevention and treatment of thrombosis in organ and tissue transplantation.
- the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism provided in the present disclosure has a direct, reversible and specific anti-thrombin function and also inhibits the GPIIb/IIIa receptors, which can achieve the anticoagulant and antithrombotic effect at a low dose. At the same time, the bleeding risk is reduced, and problems such as dose matching, bleeding, coordination and the like caused by drug combination are avoided.
- the thrombin refers to a proteolytic enzyme formed from a thrombin precursor (an essential component in blood plasma) that can promote blood coagulation by catalyzing the conversion of fibrinogen to fibrin.
- Platelet GPIIb/IIIa receptor is an adhesive glycoprotein on the surface of platelets, which is a member of integrin families. Each inactivated platelet has approximately 50,000 to 80,000 GPIIb/IIIa receptor molecules on its surface and is the most abundant integrin on the platelet surface.
- Amino acid refer to a general term for a class of organic compounds containing amino and carboxyl groups, which is a basic constituent unit of a protein and is a basic substance of proteins required for animal nutrition.
- Acidic amino acid refers to an amino acid having an isoelectric point of less than 7, including aspartic acid (Asp) and glutamic acid (Glu).
- the N-methyl amino acid refers to an amino acid obtained by substitution of an amino in the amino acids with a methyl.
- a derivative in which a benzene ring is substituted means a derivative of an amino acid in which a benzene ring of the amino acid is substituted with a linear or branched alkyl, a halogen, an alkoxy, an amide, an acyloxy or the like.
- a C1-C6 alkyl means an alkyl having 1 to 6 carbon atoms
- a C2-C10 acyl means an acyl having 2 to 10 carbon atoms.
- An embodiment of the present disclosure provides a multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism, said compound having a structure represented by Formula (1): A-L-B-L'-C Formula (1), wherein A and B are thrombin binding sites, C is a platelet GPIIb/IIIa receptor binding site, L is a first linker, and L' is a second linker.
- the first linker L connects A and B together to form a A-L-B structure
- the second linker L' connects the A-L-B structure and a C structure together to form the structure represented by Formula (1).
- the A-L-B structure can be directly connected to the C structure to form a multi-target antagonistic compound.
- L' may be a structure represented by Formula (2): ((Gly) n1 -(Ser) n2 ) n3 Formula (2).
- n1 is 1, 2, 3 or 4
- n2 is 0 or 1
- n3 is 0, 1, 2 or 3.
- L' has a structure of Gly-Gly-Gly-Gly-Ser or Gly-Gly-Gly-Ser.
- L' may be a structure represented by Formula (3): (Glu-Ala-Ala-Ala-Lys) n1 Formula (3), wherein n1 is 0, 1, 2 or 3.
- L' has a structure of Glu-Ala-Ala-Ala-Lys.
- L' may be a structure represented by Formula (4): (Arg-Val-Leu-Ala-Glu-Ala) n1 Formula (4), wherein n1 is 0, 1, 2 or 3.
- L' has a structure of Arg-Val-Leu-Ala-Glu-Ala.
- A has a structure represented by Formula (5): A1-A2-A3-A4 Formula (5), wherein A1 is D-Phe; A2 is Pro or Pip; A3 is Arg, Lys, Orn or Har; and A4 is Pro, D-Pro or Ser.
- Pip refers to 4-aminopiperidinyl-4-carboxy
- Orn refers to ornithine
- Har refers to homoarginine.
- A has a structure of D-Phe-Pro-Arg-Pro.
- B has a structure represented by Formula (6): B1-B2-B3-B4-B5 Formula (6), wherein B1 is a dipeptide consisting of any two acidic amino acids; B2 is Val, Leu, Ile, Nle or Phe; B3 is Hyp, Ser, Pro or an N-methyl amino acid; B4 is a dipeptide consisting of any two acidic amino acids; B5 is an amino acid selected from the group consisting of Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro, or B5 is a dipeptide comprising at least one amino acid selected from Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro.
- Nle represents norleucine
- Hyp represents hydroxyproline.
- B has a structure of Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu.
- C has a structure represented by Formula (7): Cys-Har-C1-Asp-Trp-Pro-C2 Formula (7), wherein C1 is Gly or Ser; C2 is Cys or a structure obtained by replacing -OH in Cys with -NH 2 ; and a disulfide bond is formed between two mercapto groups in the Formula (7).
- Har represents homoarginine.
- L has a structure represented by Formula (8): L1-L2-L3-L4-Gly-Asp-L5 Formula (8), wherein L1 is Gly, Ala, Val or Gly-Gly; L2 is Gly or Cys; L3 is Gly, Gly-Gly, Gly-Gly-Gly or a dextrorotatory amino acid; L4 is Asn or Gln; L5 is selected from one of Phe, Tyr, a derivative in which a benzene ring of Phe is substituted, and a derivative in which a benzene ring of Tyr is substituted.
- L1 is preferably Gly-Gly
- L2 is preferably Gly
- L3 is preferably Gly
- L4 is preferably Asn
- L5 is preferably Phe.
- A-L-B is selected from one of sequences shown in SEQ ID No. 1 to SEQ ID No. 3.
- phenylalanine at the N-terminal is D-phenylalanine.
- said compound has a structure represented by Formula (9): X-A-L-B-L'-C-Y Formula (9), wherein X is selected from one of hydrogen, one or two C1-C6 alkyl groups, one or two C2-C10 acyl groups, benzyloxycarbonyl or tert-butoxycarbonyl, in which optionally, the C1-C6 alkyl group may be methyl or ethyl; Y is selected from one of OH, C1-C6 alkoxy, amino, amino substituted by one or two C1-C4 alkyl, in which in an embodiment of the present disclosure, Y is OH or NH 2 .
- X is selected from one of hydrogen, one or two C1-C6 alkyl groups, one or two C2-C10 acyl groups, benzyloxycarbonyl or tert-butoxycarbonyl, in which optionally, the C1-C6 alkyl group may be methyl or ethyl
- Y is
- the compound when the compound has the structure shown in SEQ ID No.5 and Y at the C-terminal is NH 2 , the compound binds to the platelet GPIIb/IIIa receptor for a longer time and has a better platelet inhibitory function.
- the alkyl group may be a linear structure or a branched structure
- the acyl group may be a linear structure or a branched structure, wherein when X is two C1-C6 alkyl groups, the kinds of the two C1-C6 alkyl groups may be the same or different; wherein when X is two C2-C10 acyl groups, the kinds of the two C2-C10 acyl groups may be the same or different.
- Y is an amino substituted by two C1-C4 alkyls
- the kinds of the C1-C4 alkyl-substituted amino groups may be the same or different.
- the compound comprises a polypeptide sequence of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- phenylalanine at the N-terminal is D- phenylalanine.
- said compound is selected from one of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- a salt of the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism is provided.
- the salt is in a form of a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to a salt suitable for being contact with human or animal tissues without excessive toxicity, stimulation, allergies, and the like.
- the pharmaceutically acceptable salt is well known in the art.
- Such a salt can be prepared in the final separation and purification of the peptide compound of the present disclosure, and also can be separately prepared by reacting a free base or acid with a suitable organic or inorganic acid or base.
- Representative acid addition salts include, but are not limited to, acetate, trifluoroacetate, dihexanoate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, mesylate, oxalate, propionate, phosphate, glutamate, bicarbonate, p-toluenesulfonate.
- the salt is an acetate, trifluoroacetate or hydrochloride salt of the compound, and particularly preferably, the salt is an acetate salt or a trifluoroacetate salt of the compound.
- a method for preparing the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism of the present disclosure comprises the steps of: (1) sequentially connecting protected amino acids or fragments starting from a carboxyl terminal according to a polypeptide sequence using a solid phase synthesis method, to obtain a polypeptide-Wang resin in which side chains of amino acids are all protected; (2) subjecting the polypeptide-Wang resin in which side chains of amino acids are all protected to acid hydrolysis with an acid hydrolyzing agent to obtain a crude linear polypeptide; (3) cyclizing the crude linear polypeptide to form a disulfide bond and then purifying the resultant with high-pressure preparative liquid chromatography, to obtain a polypeptide sequence.
- a pharmaceutical composition comprising a multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism of the present disclosure or a salt of the compound as an active ingredient.
- the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
- the pharmaceutical composition may be in a form of an injection or a microemulsion.
- the pharmaceutically acceptable carriers commonly used in the art can be selected and used according to the form of the pharmaceutical composition.
- the content of the active ingredient is not less than 85%.
- the kind of the carrier includes but is not limited to physiological saline.
- the pharmaceutical composition of the present disclosure can be used for the treatment and/or prevention of thrombotic diseases, and its main functions include anticoagulation, antithrombosis and antiplatelet aggregation.
- a medicament comprising the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism or a salt of the compound as an active ingredient is administered to a subject.
- use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of peripheral arterial thrombosis, arterial and venous bypass thrombosis is also provided.
- use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of progressive ischemic stroke is also provided.
- use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of acute pulmonary embolism is also provided.
- the present disclosure also provides use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of thrombosis in organ and tissue transplantation, in the manufacture of a medicament for the treatment of acute coronary syndromes, percutaneous coronary intervention, or treatment with a coronary stent placed in PCI, in the manufacture of a medicament for the prevention and treatment of acute pulmonary embolism, and in the manufacture of a medicament for the prevention and treatment of thrombosis in organ and tissue transplantation.
- the uses described in the present disclosure include the manufacture of a medicament comprising the compound of the present disclosure, and the dosage form of the medicament includes but is not limited to a lyophilized powder for injection, an injection, a microemulsion, a microsphere, a micelle and other dosage forms.
- the antithrombotic medicament includes medicaments for the treatment or prevention of peripheral arterial occlusive diseases (functioning through anticoagulation, antithrombosis, antiplatelet aggregation), progressive ischemic stroke, acute coronary syndromes and the like.
- the antithrombotic medicament may also include medicaments for the prevention of the thrombosis of arteriovenous fistulas in a hemodialysis patient during VAF and VAG surgeries.
- Table 1 Name Manufacturer Specification Lot No. Sodium citrate Tianjin Baishi Chemical Co., Ltd. 500 g/bottle 20050318 0.9% NaCl injection Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd. 250 mL/bottle 11806471 PT Assay Kit Shaanxi Ark Biotechnology Co., Ltd. 10 ⁇ 2 ml 20140913 APPT Assay Kit Shaanxi Ark Biotechnology Co., Ltd. 10 ⁇ 2 ml 20141012
- Table 2 Name Manufacturer Model Electronic balance Sartorius Scientific Instruments (Beijing) Co., Ltd.
- Example 1 is used to illustrate a compound according to one embodiment of the present disclosure and its preparation process.
- Linear polypeptide 1-resin was Fmoc-D-Phe-Pro-Arg(pbf)-Pro-Gly-Gly-Gly-Gly-Asn(Trt)-Gly-Asp(OtBu)-Ile-Pro-Glu(OtBu)-Glu(OtBu)-Tyr(OtBu)-Leu-Gly-Gly-Gly-Gly-Ser(Trt)-Cys(Trt)-Har-Gly-Asp(OtBu)-Trp-Pro-Cys(Trt)-Wang.
- Fmoc-Gly-Gly-Gly-Gly-Gly-Gly-OH, Fmoc-Leu-OH, Fmoc-Tyr(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Ile-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gly-Gly-Gly-Gly-OH, Fmoc-Pro-OH, Fmoc- Arg(pbf)-OH, Fmoc-Pro-OH and Fmoc-D-Phe-OH were sequentially introduced with the above method, to obtain polypeptid
- Polypeptide 1 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 4): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gly Gly Gly Gly Ser Cys Har Gly Asp Trp Pro Cys. 10 g of the linear polypeptide 1 prepared in step 4 was dissolved in 200 ml pure water, and thereto a 5% I 2 solution was slowly add dropwise under stirring. The reaction was detected by HPLC. After the reaction was completed, the target product was purified by high performance liquid chromatography and lyophilized to obtain the final product polypeptide 1 in a weight of 1 g. Detection results of mass spectrometry of polypeptide 1 are shown in Figure 1 .
- Polypeptide 2 was prepared in the same manner as Example 1, except that the L' fragment was Glu Ala Ala Ala Lys, to obtain polypeptide 2 in a product weight of 1.2 g. Detection results of mass spectrometry of polypeptide 2 are shown in Figure 2 .
- Polypeptide 2 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 5): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Glu Ala Ala Ala Lys Cys Har Gly Asp Trp Pro Cys
- Polypeptide 3 was prepared in the same manner as Example 1, except that the fragment Gly Gly Gly Gly Gly Ser (i.e., the fragment L') was removed to obtain polypeptide 3 in a product weight of 1.5 g. Detection results of mass spectrometry of polypeptide 3 are shown in Figure 3 .
- Polypeptide 3 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 6): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Glu Ala Ala Ala Lys Cys Har Gly Asp Trp Pro Cys
- Polypeptide 4 was prepared in the same manner as Example 1, except that the L' fragment was Arg Val Leu Ala Glu Ala to obtain polypeptide 4 in a product weight of 0.86 g. Detection results of mass spectrometry of polypeptide 4 are shown in Figure 4 .
- Polypeptide 4 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 7): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Glu Ala Ala Ala Lys Cys Har Gly Asp Trp Pro Cys
- Test examples 1 to 4 are used to demonstrate the anticoagulant and antiplatelet aggregation effect of polypeptides 1 to 4 prepared in Examples 1 to 4 on human blood.
- 30 ml of venous blood was drawn from a healthy volunteer, quickly injected into a plastic tube containing 3 ml of 3.8% sodium citrate solution, and then gently mixed by inversion up and down.
- the drawn blood was centrifuged at 810 rpm for 8 minutes to obtain platelet rich plasma (PRP), which was taken out, then the blood sample was further centrifuged at 3510 rpm for 8 minutes to obtain platelet poor plasma (PPP).
- PRP platelet rich plasma
- PPP platelet poor plasma
- PT prothrombin time
- TT thrombin time
- APTT activated partial thromboplastin time
- a platelet aggregation instrument was started up and preheated for 30 minutes, and then calibrated with PPP.
- Into the test cups 270 ⁇ l of PRP was added, and then 10 ⁇ l of polypeptide 1, polypeptide 2, polypeptide 3 or polypeptide 4 (1.0 ⁇ 10 -7 mol/L) and/or 20 ⁇ l of physiological saline were added respectively, till a total volume of 300 ⁇ l.
- 5 ⁇ l of inducer ADP and 5 ⁇ l of epinephrine were added to start the test.
- the test was completed, and the maximum aggregation rate within the 5 minutes was recorded, and the data and maps were printed.
- This test example is used to demonstrate the antithrombotic effect of polypeptide 2 prepared in EXAMPLE 2 in rats.
- Rats were randomly divided into groups, 5 to 10 rats per group.
- 1) Model control group intravenous injection of the same volume of physiological saline; 2) 6 dose groups of polypeptide 2: starting from 1.5 mg/kg+3.75 mg/kg/h, which was decreased to 1 mg/kg+2.5 mg/kg/h, 0.5 mg/kg+1.25 mg/kg/h, 0.25 mg/kg+0.75 mg/kg/h, 0.125 mg/kg+0.375 mg/kg/h, and 0.041 mg/kg+0.125 mg/kg/h; 3) 5 dose groups of positive control enoxaparin: starting from 30 U/kg+45 U/kg/h, which was increased to 60 U/kg+60 U/kg/h, 30 U/kg+120 U/kg/h , 90 U/kg+120 U/kg/h, 60 U/kg +240 U/kg/h, 4) 5 dose groups of positive control bivalirudin: starting from 0.5 mg/kg+2 mg/kg/h, which was decreased to 0.35 mg/
- the first dose of a drug was dissolved in 2 mL of physiological saline for single bolus injection.
- the maintaining dose of drug was dissolved in 9 ml of physiological saline, and placed in a double-channel micro-injection pump, which was dripped off within 90 minutes at a dripping speed of 0.1 ml/min.
- the sham operation group was administered with the same volume of physiological saline.
- the rats were fasted with free access to water overnight before the experiment.
- the rats were anesthetized with intravenous injection of a 20% urethane solution at 5 ml/kg, fixed in the supine position, and then, the bilateral common carotid arteries, external jugular veins and inferior vena cava were isolated.
- the external jugular vein was subjected to intubation for administration; the common carotid artery on one side was subjected to intubation for blood collection to determine the blood coagulation functions PT and APTT, and the common carotid artery on the other side was used for the establishment of an arterial thrombosis model; and the inferior vena cava was used for the establishment of a venous thrombosis model.
- the blood samples were taken before administration, administration for 60 minutes, and before termination of administration, respectively, to determine their activated partial thromboplastin time (APTT) and prothrombin time (PT).
- the blood samples were centrifuged at 3510 rpm for 8 minutes to obtain platelet poor plasma (PPP). Reagent reconstruction and preservation were performed according to the operation requirements of the kit. Immediately after each blood sample was placed into a test cup and then PT and APTT reagents were added, the test was started. After the test was completed, results were recorded.
- APTT activated partial thromboplastin time
- PT prothrombin time
- a filter paper with a 3 mm diameter and immersed with 35% FeCl 3 solution was applied below the common carotid artery, below which a small piece of a plastic film (2.5 cm ⁇ 2.0 cm) was placed to protect surrounding tissues.
- the body temperature was detected with a temperature probe in the distal end of the artery, and the time required from the beginning of stimulation to the point when the temperature decreased by 2.5 degrees was examined as the vascular occlusion time.
- a filter paper with a 3 mm diameter and immersed with 35% FeCl 3 solution was applied below the inferior vena cava, below which a small piece of a plastic film (2.5 cm ⁇ 2.0 cm) was placed to protect surrounding tissues. 15 minutes later, the filter paper was removed. And then, after observation for 45 minutes, the blood vessels and local tissues were rinsed with warm physiological saline, and the covered blood vessels were cut off. The thrombus which attached to the blood vessel walls was peeled off to be weighed on a tin foil for its wet weight, and then weighed overnight at room temperature for its dry weight. The administration was continued until the completion of the experiment.
- polypeptide 2 can dose-dependently inhibit FeCl 3 -induced inferior vena cava thrombosis in rats, inhibit FeCl 3 -induced common carotid arterial thrombosis in rats, and prolong APTT and PT in rats.
- Figure 5 shows effect of polypeptide 2 on FeCl 3 -induced inferior vena cava thrombosis in rats, with * P ⁇ 0.05, **P ⁇ 0.01 compared with the model group.
- Figure 6 shows effect of polypeptide 2 on FeCl 3 -induced common carotid arterial thrombosis in rats, which shows the fold of change in the arterial occlusion time, with * P ⁇ 0.05, ** P ⁇ 0.01 compared with the model group.
- Figure 7 shows effect of polypeptide 2 on APTT in rats.
- Figure 8 shows effect of polypeptide 2 on PT in rats.
- This test example is used to illustrate a pharmacodynamic test of thrombus inhibition in rabbits by intravenous maintenance administration of polypeptide 2 prepared in EXAMPLE 2.
- polypeptide 2 test solution 200 mg of polypeptide 2 was accurately weighed with an electronic balance and was prepared into 10 mg/mL stock solution with physiological saline, which was sufficiently mixed well, sub-packaged in 5 mL for each, and stored at -20°C. During the test, an appropriate amount of the stock solution was diluted and used by calculation based on the body weight of the rabbits.
- 3% Sodium pentobarbital solution 3 g of sodium pentobarbital was accurately weighed and metered with distilled water to a volume of 100 ml. 3.8% Sodium citrate solution: 4.33g of sodium citrate dihydrate was accurately weighed and metered with physiological saline to a volume of 100 ml, to obtain a 3.8% solution for use.
- Epinephrine solution 1.319 ml of stock solution was taken and metered to 100 ml with physiological saline to prepare a 60 ⁇ M solution, which was stored at 4°C in a refrigerator and sub-packaged before use.
- ADP solution 14.3 mg of ADP was accurately weighed and dissolved in 5 ml of physiological saline to obtain a 6000 ⁇ mol/L ADP solution which was stored at 4°C, and was diluted with physiological saline to 600 ⁇ mol/L before the experiment.
- Aluminum foil The foil was measured with a ruler and cut to 2.5 cm ⁇ 2.5 cm, numbered and weighed; nonabsorbable surgical suture: 8 cm long of the suture was taken with a ruler and weighed.
- 50% ferric chloride solution 50 g of ferric chloride was taken and dissolved in 100 mL of distilled water.
- mice 10 rabbits were randomly divided into 3 groups, 2 to 3 rabbits per group.
- Sham operation group NS: Intravenous injection of the same volume of physiological saline, with the same operation method as above; 2) polypeptide 2 administration group: 8.0mg/kg+20.0 mg/kg/h; 3) positive control enoxaparin group: 50 U/kg+150 U/kg/h.
- the first dose of the drug to be tested was dissolved in 2 mL of physiological saline for single bolus injection.
- the maintaining dose was dissolved in 9 ml of physiological saline, and placed in a double-channel micro-injection pump, which was dripped off within 90 minutes at a dripping speed of 1 ml/min.
- the sham operation group was administered with the same volume of physiological saline.
- Table 11 shows the effect of intravenous maintenance administration of polypeptide 2 on the blood coagulation function APTT in rabbits (S, ( x ⁇ s ));
- Table 12 shows the effect of intravenous maintenance administration of polypeptide 2 on the blood coagulation function PT in rabbits (S, ( x ⁇ s ));
- Table 13 shows the effect of intravenous maintenance administration of polypeptide 2 on the blood coagulation function TT in rabbits (S, ( x ⁇ s ));
- Table 14 shows the effect of intravenous maintenance administration of polypeptide 2 on ACT in rabbits (S, ( x ⁇ s )).
- the dose unit is (mg/kg+mg/kg/h).
- the results show that the intravenous maintenance administration of polypeptide 2 can inhibit platelet aggregation in rabbits. After the administration was terminated, the inhibition of platelet aggregation was gradually weakened over time.
- This test example is used to illustrate antithrombotic as well as anticoagulant and antiplatelet aggregation experiments in vivo with single intravenous administration in rabbits.
- Experimental animals 48 healthy adult male rabbits, weighed to be 2 to 2.5 kg, provided by Xi'an Dilepu Biological Resources Development Co., Ltd., Animal production license number: SCXK (Shaanxi) 2006-001.
- Samples to be tested polypeptide 2 having a peptide content of 97.21%.
- Positive drugs enoxaparin and bivalirudin.
- the single intravenous administration of polypeptide 2 in each dose group for 5 min can inhibit platelet aggregation in rabbits to different extents.
- the medium dose group of polypeptide 2 in 6.0 mg/kg and the high dose group of polypeptide 2 in 12.0 mg/kg ( P ⁇ 0.05 ); and the antiplatelet effect in the medium dose group of polypeptide 2 was significantly better than that in the bivalirudin and enoxaparin groups.
- the inhibition on platelet aggregation in rabbits was gradually weakened.
- Polypeptide 2 in each dose group can prolong the PT in rabbits to different extents, and the prolongation of PT was gradually weakened over time within 15 min.
- Polypeptide 2 in each dose group can prolong the ACT in rabbits to different extents, and the prolongation of ACT was gradually weakened over time within 15 min.
- polypeptide 2 can inhibit FeCl 3 -induced femoral arterial thrombosis in rabbits and dose-dependently inhibit femoral arterial and venous bypass thrombosis in rabbits, in which the antithrombotic effect in the medium and high doe groups thereof is superior to that in the bivalirudin group; as well as polypeptide 2 can inhibit platelet aggregation in rabbits in a dose-dependent manner, affect the blood coagulation function in rabbits and prolong APTT, PT, TT and ACT.
- This test example is used to demonstrate the protective effect of polypeptide 2 on progressive ischemic stroke.
- Tables 25 and 26 show that, polypeptide 2 at the doses of 0.5+1.25 and 1.0+2.5 (mg/kg+mg/kg/h) reduced the cerebral infarct volume from (23.41+10.08)% to (11.12 ⁇ 6.56)% and (8.01 ⁇ 6.66)% 24 hours after the surgery, respectively; and the neurobehavioral injury was also improved, indicating the protective effect on the experimental cerebral infarction.
- Table 25 The test results in Tables 25 and 26 show that, polypeptide 2 at the doses of 0.5+1.25 and 1.0+2.5 (mg/kg+mg/kg/h) reduced the cerebral infarct volume from (23.41+10.08)% to (11.12 ⁇ 6.56)% and (8.01 ⁇ 6.66)% 24 hours after the surgery, respectively; and the neurobehavioral injury was also improved, indicating the protective effect on the experimental cerebral infarction. Table 25.
- This test example is used to demonstrate the protective effect of polypeptide 2 on thrombin-induced pulmonary embolism in mice.
- mice Kunming mice, male, 6 to 8 weeks old, 20 g to 25 g, provided by experimental animal center of Xi'an Jiaotong University. Animal production license number SCXK (Shaanxi) 2012-003.
- mice were randomly divided into 7 groups with 10 mice per group, in which group 1 was physiological saline group, group 2 was model control group, group 3 was positive control group of enoxaparin 0.5 mg/kg, group 4 was positive control group of bivalirudin 8 mg/kg, group 5 was low dose group of polypeptide 2 at 2.5 mg/kg, group 6 was medium dose group of polypeptide 2 at 5.0 mg/kg, and group 7 was high dose group of polypeptide 2 at 10.0 mg/kg. Except that physiological saline group and model control group were subjected to tail intravenous injection of 200 ⁇ l physiological saline, the other groups were given according to the doses, respectively.
- mice in physiological saline group were administered with 100 ⁇ l physiological saline through tail intravenous injection and the other groups were each administered with 100 ⁇ l thrombin based on 1500 u/kg (80% to 90% of the lethal dose) through tail intravenous injection.
- the mice were observed after the administration for their death within 15 min. Mice those did not die within 15 min were subjected to the treatments as follows.
- the lung coefficient significantly increased, which had a very significant difference ( P ⁇ 0.01 ) compared with the physiological saline group; the lung coefficient in the bivalirudin 8 mg/kg group decreased, which had a significant difference (P ⁇ 0.05) compared with the model group; and the lung coefficient of mice in the high dose group of polypeptide 2 at 10.0 mg/kg group decreased, which had a very significant difference compared with the model group (P ⁇ 0.01).
- the results are shown in Table 27 and Figure 16 , indicating that polypeptide 2 has protective effect on thrombin-induced pulmonary embolism in mice. Table 27.
- the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism of the invention has direct, reversible and specific anti-thrombin function and also has function of inhibiting the GPIIb/IIIa receptors, which can achieve the anticoagulant and antithrombotic effect at a low dose. At the same time, the bleeding risk is reduced, and problems such as dose matching, bleeding, coordination caused by drug combination are avoided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- The present invention relates to the biomedical field, in particular to a multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism as well as a preparation method thereof and use thereof.
- Thrombosis is an early event during the occurrence of thrombotic diseases and runs through the development of the diseases. Platelet activation and activation of the blood coagulation system play an important role in the process of thrombosis, and are closely related to each other in vivo. Thrombin, which is produced when the blood coagulation system is activated, is a potent platelet activating factor to activate platelets, which in turn facilitates the blood coagulation process. The principle of the prevention and treatment of the thrombotic diseases is to improve the hypercoagulable state, to prevent thrombus extension and new thrombus formation, to dissolve thrombus and then to clear or rebuild the blood flow path, thereby preventing ischemia and necrosis of tissues. Methods for treating the thrombotic diseases include antithrombotic, thrombolytic, interventional and surgical therapies. Among them, the antithrombotic therapy includes antiplatelet and anticoagulant therapies, and it has been of concern as a foundation for the treatment of thrombotic diseases, especially cardiovascular diseases. Anticoagulant drugs prevent the blood coagulation process and thereby prevent thrombosis by acting on blood coagulation factors; antiplatelet drugs inhibit thrombosis by functions of inhibiting platelet adhesion, aggregation and release. Currently, clinically used thrombin inhibitors mainly include low molecular weight heparin and bivalirudin; and platelet GPIIb/IIIa receptor antagonists mainly include lamivudine, tirofiban, etc. These drugs have side effects such as bleeding tendency, and are subjected to some application limitations. More importantly, all of these drugs inhibit thrombosis through a single target site, and currently, drugs for different target sites are often used in combination clinically, so as to achieve clinical effects in terms of increase in efficacy and reduction of side effects. However, currently, for the drug combination, there are problems, such as dose matching, bleeding, coordination, which has great influences on the clinical antithrombotic effect.
- Therefore, it is necessary to develop a technical solution which is capable of inhibiting thrombosis by multi-target inhibition, so as to achieve the effect of simultaneous action on different target sites by administration of a single drug and to avoid the problems caused by the drug combination.
- An object of the present invention is to overcome the defects existing in the prior art and to provide a multi-target antagonistic compound which is capable of simultaneously targeting thrombin and platelet GPIIb/IIIa receptors.
- The present disclosure provides a multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism, said compound having a structure represented by Formula (1):
A-L-B-L'-C Formula (1),
wherein A and B are thrombin binding sites, C is a platelet GPIIb/IIIa receptor binding site, L is a first linker, and L' is a second linker. - Optionally, L' has a structure represented by Formula (2):
((Gly)n1-(Ser)n2)n3 Formula (2),
wherein n1 is 1, 2, 3 or 4; n2 is 0 or 1; and n3 is 0, 1, 2 or 3. - Optionally, L' has a structure represented by Formula (3):
(Glu-Ala-Ala-Ala-Lys)n1 Formula (3),
wherein n1 is 0, 1, 2 or 3. - Optionally, L' has a structure represented by Formula (4):
(Arg-Val-Leu-Ala-Glu-Ala)n1 Formula (4),
wherein n1 is 0, 1, 2 or 3. - Optionally, A has a structure represented by Formula (5):
A1-A2-A3-A4 Formula (5),
wherein A1 is D-Phe; A2 is Pro or Pip; A3 is Arg, Lys, Orn or Har; and A4 is Pro, D-Pro or Ser. - Optionally, B has a structure represented by Formula (6):
B1-B2-B3-B4-B5 Formula (6),
wherein B1 is a dipeptide consisting of any two acidic amino acids; B2 is Val, Leu, Ile, Nle or Phe; B3 is Hyp, Ser, Pro or an N-methyl amino acid; B4 is a dipeptide consisting of any two acidic amino acids; B5 is an amino acid selected from the group consisting of Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro, or B5 is a dipeptide comprising at least one amino acid selected from Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro. - Optionally, C has a structure represented by Formula (7):
Cys-Har-C1-Asp-Trp-Pro-C2 Formula (7),
wherein C1 is Gly or Ser; C2 is Cys or a structure obtained by replacing -OH in Cys with -NH2; and a disulfide bond is formed between two mercapto groups in the Formula (7). - Optionally, L has a structure represented by Formula (8):
L1-L2-L3-L4-Gly-Asp-L5 Formula (8),
wherein L1 is Gly, Ala, Val or Gly-Gly; L2 is Gly or Cys; L3 is Gly, Gly-Gly, Gly-Gly-Gly or a dextrorotatory amino acid; L4 is Asn or Gln; L5 is one selected from Phe, Tyr, a derivative in which a benzene ring of Phe is substituted, and a derivative in which a benzene ring of Tyr is substituted. - Optionally, A-L-B is selected from one of the polypeptide sequences shown in SEQ ID No. 1 to SEQ ID No. 3.
- Optionally, said compound has a structure represented by Formula (9):
X-A-L-B-L'-C-Y Formula (9),
wherein X is one selected from hydrogen, one or two C1-C6 alkyl, one or two C2-C10 acyl, benzyloxycarbonyl and tert-butoxycarbonyl; Y is one selected from OH, C1-C6 alkoxy, an amino, and an amino substituted with one or two C1-C4 alkyl. - Optionally, said compound comprises a polypeptide sequence of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- Optionally, said compound is selected from one of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- The present disclosure further provides a salt of the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism.
- Optionally, said salt is an acetate salt of the compound or a trifluoroacetate salt of the compound.
- The present disclosure further provides a method for preparing the compound of the present disclosure, wherein the method comprises the steps of:
- (1) sequentially connecting protected amino acids or fragments starting from a carboxyl terminal according to a polypeptide sequence using a solid phase synthesis method, to obtain a polypeptide-Wang resin in which side chains of amino acids are all protected; (2) subjecting the polypeptide-Wang resin in which side chains of amino acids are all protected to acid hydrolysis with an acid hydrolyzing agent to obtain a crude linear polypeptide; and (3) cyclizing the crude linear polypeptide to form a disulfide bond and then purifying the resultant with high-pressure preparative liquid chromatography, to obtain a polypeptide sequence.
- The present disclosure also provides a pharmaceutical composition, wherein said pharmaceutical composition comprises the compound of the present disclosure or a salt of the compound of the present disclosure as an active ingredient.
- Optionally, the dosage form of said pharmaceutical composition is an injection, a tablet, a capsule, a pill, a powder, a granule, a suspension or an emulsion.
- The present disclosure also provides use of the compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of peripheral arterial thrombosis, arterial and venous bypass thrombosis. The present disclosure also provides use of the compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of progressive ischemic stroke, in the manufacture of a medicament for the treatment of thrombosis in acute coronary syndromes, percutaneous coronary intervention, or therapy with a coronary stent in PCI, in the manufacture of a medicament for the prevention and treatment of acute pulmonary embolism, or in the manufacture of a medicament for the prevention and treatment of thrombosis in organ and tissue transplantation.
- The multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism provided in the present disclosure has a direct, reversible and specific anti-thrombin function and also inhibits the GPIIb/IIIa receptors, which can achieve the anticoagulant and antithrombotic effect at a low dose. At the same time, the bleeding risk is reduced, and problems such as dose matching, bleeding, coordination and the like caused by drug combination are avoided.
-
-
Figure 1 shows detection results of mass spectrometry ofpolypeptide 1. -
Figure 2 shows detection results of mass spectrometry ofpolypeptide 2. -
Figure 3 shows detection results of mass spectrometry ofpolypeptide 3. -
Figure 4 shows detection results of mass spectrometry ofpolypeptide 4. -
Figure 5 shows effect ofpolypeptide 2 on FeCl3-induced inferior vena cava thrombosis in rats. -
Figure 6 shows effect ofpolypeptide 2 on FeCl3-induced common carotid arterial thrombosis in rats. -
Figure 7 shows effect ofpolypeptide 2 on APTT in rats. -
Figure 8 shows effect ofpolypeptide 2 on PT in rats. -
Figure 9 is a flowchart of an arterial thrombosis model test. -
Figure 10 shows effect of single intravenous administration ofpolypeptide 2 on the dry weight of thrombus of FeCl3-induced femoral artery thrombosis in rabbits. -
Figure 11 shows effect of 15 minutes after single intravenous administration ofpolypeptide 2 on the dry weight of thrombus of femoral arterial and venous bypass thrombosis in rabbits. -
Figure 12 shows effect of single intravenous administration ofpolypeptide 2 on platelet aggregation in rabbits (an inhibitory rate of platelet aggregation). -
Figure 13 shows effect of single intravenous administration ofpolypeptide 2 on APTT in rabbits. -
Figure 14 shows effect of single intravenous administration ofpolypeptide 2 on PT in rabbits. -
Figure 15 shows effect of single intravenous administration ofpolypeptide 2 on ACT in rabbits. -
Figure 16 shows effect ofpolypeptide 2 on the lung coefficient in a thrombin (1500 u/kg)-induced mouse pulmonary embolism model. - The present disclosure will be described in detail by way of specific embodiments hereinafter. It should be understood that the following embodiments are given for an illustrative purpose only and are not intended to limit the scope of the present disclosure. Those skilled in the art can make various modifications and replacements to the present disclosure without departing from the spirit and scope of the present disclosure.
- In the present disclosure, the thrombin refers to a proteolytic enzyme formed from a thrombin precursor (an essential component in blood plasma) that can promote blood coagulation by catalyzing the conversion of fibrinogen to fibrin. Platelet GPIIb/IIIa receptor is an adhesive glycoprotein on the surface of platelets, which is a member of integrin families. Each inactivated platelet has approximately 50,000 to 80,000 GPIIb/IIIa receptor molecules on its surface and is the most abundant integrin on the platelet surface. Amino acid refer to a general term for a class of organic compounds containing amino and carboxyl groups, which is a basic constituent unit of a protein and is a basic substance of proteins required for animal nutrition. The amino acids in the present disclosure are expressed by their conventional abbreviations in the art. Acidic amino acid refers to an amino acid having an isoelectric point of less than 7, including aspartic acid (Asp) and glutamic acid (Glu). The N-methyl amino acid refers to an amino acid obtained by substitution of an amino in the amino acids with a methyl. A derivative in which a benzene ring is substituted means a derivative of an amino acid in which a benzene ring of the amino acid is substituted with a linear or branched alkyl, a halogen, an alkoxy, an amide, an acyloxy or the like. A C1-C6 alkyl means an alkyl having 1 to 6 carbon atoms, and a C2-C10 acyl means an acyl having 2 to 10 carbon atoms.
- An embodiment of the present disclosure provides a multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism, said compound having a structure represented by Formula (1): A-L-B-L'-C Formula (1), wherein A and B are thrombin binding sites, C is a platelet GPIIb/IIIa receptor binding site, L is a first linker, and L' is a second linker. Herein, the first linker L connects A and B together to form a A-L-B structure, and the second linker L' connects the A-L-B structure and a C structure together to form the structure represented by Formula (1). In an embodiment of the present disclosure, the A-L-B structure can be directly connected to the C structure to form a multi-target antagonistic compound.
- In an embodiment of the present disclosure, L' may be a structure represented by Formula (2): ((Gly)n1-(Ser)n2)n3 Formula (2). In the formula (2), n1 is 1, 2, 3 or 4; n2 is 0 or 1; and n3 is 0, 1, 2 or 3.
- In a preferred embodiment, L' has a structure of Gly-Gly-Gly-Gly-Ser or Gly-Gly-Gly-Ser.
- In an embodiment of the present disclosure, L' may be a structure represented by Formula (3): (Glu-Ala-Ala-Ala-Lys)n1 Formula (3), wherein n1 is 0, 1, 2 or 3.
- In a preferred embodiment, L' has a structure of Glu-Ala-Ala-Ala-Lys.
- In an embodiment of the present disclosure, L' may be a structure represented by Formula (4): (Arg-Val-Leu-Ala-Glu-Ala)n1 Formula (4), wherein n1 is 0, 1, 2 or 3.
- In a preferred embodiment, L' has a structure of Arg-Val-Leu-Ala-Glu-Ala.
- In an embodiment of the present disclosure, A has a structure represented by Formula (5): A1-A2-A3-A4 Formula (5), wherein A1 is D-Phe; A2 is Pro or Pip; A3 is Arg, Lys, Orn or Har; and A4 is Pro, D-Pro or Ser. Herein, Pip refers to 4-aminopiperidinyl-4-carboxy, Orn refers to ornithine, and Har refers to homoarginine.
- In a preferred embodiment, A has a structure of D-Phe-Pro-Arg-Pro.
- In an embodiment of the present disclosure, B has a structure represented by Formula (6): B1-B2-B3-B4-B5 Formula (6), wherein B1 is a dipeptide consisting of any two acidic amino acids; B2 is Val, Leu, Ile, Nle or Phe; B3 is Hyp, Ser, Pro or an N-methyl amino acid; B4 is a dipeptide consisting of any two acidic amino acids; B5 is an amino acid selected from the group consisting of Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro, or B5 is a dipeptide comprising at least one amino acid selected from Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro. Herein, Nle represents norleucine, and Hyp represents hydroxyproline.
- In a preferred embodiment of the present disclosure, B has a structure of Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu.
- Optionally, C has a structure represented by Formula (7): Cys-Har-C1-Asp-Trp-Pro-C2 Formula (7), wherein C1 is Gly or Ser; C2 is Cys or a structure obtained by replacing -OH in Cys with -NH2; and a disulfide bond is formed between two mercapto groups in the Formula (7). Herein, Har represents homoarginine.
- Optionally, L has a structure represented by Formula (8): L1-L2-L3-L4-Gly-Asp-L5 Formula (8), wherein L1 is Gly, Ala, Val or Gly-Gly; L2 is Gly or Cys; L3 is Gly, Gly-Gly, Gly-Gly-Gly or a dextrorotatory amino acid; L4 is Asn or Gln; L5 is selected from one of Phe, Tyr, a derivative in which a benzene ring of Phe is substituted, and a derivative in which a benzene ring of Tyr is substituted. Herein, L1 is preferably Gly-Gly, L2 is preferably Gly, L3 is preferably Gly, L4 is preferably Asn, and L5 is preferably Phe.
- In a preferred case, A-L-B is selected from one of sequences shown in SEQ ID No. 1 to SEQ ID No. 3. In the sequences shown in SEQ ID No. 1 to SEQ ID No. 3, phenylalanine at the N-terminal is D-phenylalanine.
- SEQ ID No. 1: D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Tyr Glu Asp Ile Pro- Glu Glu Tyr Leu
- SEQ ID No.2: D-Phe Pro Arg Ser Gly Gly Gly Gly Asn Gly Asp Phe Glu Asp Ile Pro Glu Glu Tyr Leu
- SEQ ID No.3: D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro- Glu Glu Tyr Leu
- In an embodiment of the present disclosure, said compound has a structure represented by Formula (9): X-A-L-B-L'-C-Y Formula (9), wherein X is selected from one of hydrogen, one or two C1-C6 alkyl groups, one or two C2-C10 acyl groups, benzyloxycarbonyl or tert-butoxycarbonyl, in which optionally, the C1-C6 alkyl group may be methyl or ethyl; Y is selected from one of OH, C1-C6 alkoxy, amino, amino substituted by one or two C1-C4 alkyl, in which in an embodiment of the present disclosure, Y is OH or NH2. In a particularly preferred embodiment, when the compound has the structure shown in SEQ ID No.5 and Y at the C-terminal is NH2, the compound binds to the platelet GPIIb/IIIa receptor for a longer time and has a better platelet inhibitory function.
- Herein, the alkyl group may be a linear structure or a branched structure, and the acyl group may be a linear structure or a branched structure, wherein when X is two C1-C6 alkyl groups, the kinds of the two C1-C6 alkyl groups may be the same or different; wherein when X is two C2-C10 acyl groups, the kinds of the two C2-C10 acyl groups may be the same or different. When Y is an amino substituted by two C1-C4 alkyls, the kinds of the C1-C4 alkyl-substituted amino groups may be the same or different.
- Optionally, the compound comprises a polypeptide sequence of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7. In the polypeptide sequences shown in SEQ ID No. 4 to SEQ ID No. 7, phenylalanine at the N-terminal is D- phenylalanine.
- SEQ ID No.4: D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gly Gly Gly Gly Ser Cys Har Gly Asp Trp Pro Cys
- SEQ ID No.5: D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Glu Ala Ala Ala Lys Cys Har Gly Asp Trp Pro Cys
- SEQ ID No.6: D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Cys Har Gly Asp Trp Pro Cys
- SEQ ID No.7: D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Arg Val Leu Ala Glu Ala Cys Har Gly Asp Trp Pro Cys
- In a preferred embodiment of the present disclosure, said compound is selected from one of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- In one aspect of the present disclosure, a salt of the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism is provided.
- In the present disclosure, the salt is in a form of a pharmaceutically acceptable salt. The "pharmaceutically acceptable salt" refers to a salt suitable for being contact with human or animal tissues without excessive toxicity, stimulation, allergies, and the like. The pharmaceutically acceptable salt is well known in the art. Such a salt can be prepared in the final separation and purification of the peptide compound of the present disclosure, and also can be separately prepared by reacting a free base or acid with a suitable organic or inorganic acid or base. Representative acid addition salts include, but are not limited to, acetate, trifluoroacetate, dihexanoate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, mesylate, oxalate, propionate, phosphate, glutamate, bicarbonate, p-toluenesulfonate. Preferably, the salt is an acetate, trifluoroacetate or hydrochloride salt of the compound, and particularly preferably, the salt is an acetate salt or a trifluoroacetate salt of the compound.
- In one aspect of the present disclosure, a method for preparing the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism of the present disclosure is provided, wherein said method comprises the steps of: (1) sequentially connecting protected amino acids or fragments starting from a carboxyl terminal according to a polypeptide sequence using a solid phase synthesis method, to obtain a polypeptide-Wang resin in which side chains of amino acids are all protected; (2) subjecting the polypeptide-Wang resin in which side chains of amino acids are all protected to acid hydrolysis with an acid hydrolyzing agent to obtain a crude linear polypeptide; (3) cyclizing the crude linear polypeptide to form a disulfide bond and then purifying the resultant with high-pressure preparative liquid chromatography, to obtain a polypeptide sequence.
- In one aspect of the present disclosure, a pharmaceutical composition is also provided, wherein said pharmaceutical composition comprises a multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism of the present disclosure or a salt of the compound as an active ingredient. Optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. The pharmaceutical composition may be in a form of an injection or a microemulsion. The pharmaceutically acceptable carriers commonly used in the art can be selected and used according to the form of the pharmaceutical composition. In the pharmaceutical composition, the content of the active ingredient is not less than 85%. The kind of the carrier includes but is not limited to physiological saline. The pharmaceutical composition of the present disclosure can be used for the treatment and/or prevention of thrombotic diseases, and its main functions include anticoagulation, antithrombosis and antiplatelet aggregation. A medicament comprising the multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism or a salt of the compound as an active ingredient is administered to a subject.
- In one aspect of the present disclosure, use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of peripheral arterial thrombosis, arterial and venous bypass thrombosis is also provided. In one aspect of the present disclosure, use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of progressive ischemic stroke is also provided. In one aspect of the present disclosure, use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of acute pulmonary embolism is also provided. The present disclosure also provides use of a compound of the present disclosure or a salt of the compound of the present disclosure in the manufacture of a medicament for the prevention and treatment of thrombosis in organ and tissue transplantation, in the manufacture of a medicament for the treatment of acute coronary syndromes, percutaneous coronary intervention, or treatment with a coronary stent placed in PCI, in the manufacture of a medicament for the prevention and treatment of acute pulmonary embolism, and in the manufacture of a medicament for the prevention and treatment of thrombosis in organ and tissue transplantation. The uses described in the present disclosure include the manufacture of a medicament comprising the compound of the present disclosure, and the dosage form of the medicament includes but is not limited to a lyophilized powder for injection, an injection, a microemulsion, a microsphere, a micelle and other dosage forms. The antithrombotic medicament includes medicaments for the treatment or prevention of peripheral arterial occlusive diseases (functioning through anticoagulation, antithrombosis, antiplatelet aggregation), progressive ischemic stroke, acute coronary syndromes and the like. In addition, the antithrombotic medicament may also include medicaments for the prevention of the thrombosis of arteriovenous fistulas in a hemodialysis patient during VAF and VAG surgeries.
- Hereinafter, the specific embodiments of the present disclosure will be further described by way of examples. The instruments and reagents involved in the following examples can all be obtained by purchasing commercially available products.
- Some experimental materials in the following examples are shown in Table 1, and the instruments are shown in Table 2.
Table 1 Name Manufacturer Specification Lot No. Sodium citrate Tianjin Baishi Chemical Co., Ltd. 500 g/bottle 20050318 0.9% NaCl injection Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd. 250 mL/bottle 11806471 PT Assay Kit Shaanxi Ark Biotechnology Co., Ltd. 10×2 ml 20140913 APPT Assay Kit Shaanxi Ark Biotechnology Co., Ltd. 10×2 ml 20141012 Table 2 Name Manufacturer Model Electronic balance Sartorius Scientific Instruments (Beijing) Co., Ltd. BSA124S-CW Centrifuge Anhui Zhongke Zhongjia Scientific Instrument Co., Ltd. SC-3610 Precise microsampler Nichipet, Japan 5 µl, 100 µl, 200 µl, 1000 µl Platelet-aggregation coagulation factor analyzer Beijing Steellex Scientific Instrument Co., Ltd. LG-PABER-I Bleeding time tester Jiangsu Kangjian Medical Apparatus Co., Ltd. 5mm wide, 1mm deep Temperature tester Home-made - Example 1 is used to illustrate a compound according to one embodiment of the present disclosure and its preparation process.
- An Fmoc-Gly-2-Cl-Trt-resin (23.5 g, 16.5 mmol) with a degree of substitution of 0.7 mmol/g was subjected to deprotection of Fmoc with 2.5 L of 25% PIP/DMF solution for 25 minutes. The resin was filtered, and then washed by turns with DMF and DCM for three times, with not less than 1 minute each time. Fmoc-Gly-OH (14.8 g, 50 mmol) was added and stirred for reaction for 4 hours at 30°C. The reaction was detected for its end point by a ninhydrin method. After the reaction was completed, the resin was filtered and washed by turns with DMF and DCM for three times.
- The above steps were repeated twice to connect two additional Gly residues, finally obtaining an Fmoc-Gly-Gly-Gly-Gly-2-Cl-Trt-resin. The resulted resin was dissolved in 5 L of 30% hexafluoroisopropanol/DCM solution and stirred for reaction for 2 hours. The filtrate was collected by filtration and dried under vacuum at 30°C for 10 hours to give 7.2 g of Fmoc-Gly-Gly-Gly-Gly-OH, with a yield of 96% and a purity of 95.6%, MS m/z: 469 (M+1).
- 10 g of the Fmoc-Cys(Trt)-Wang resin (load 1.0mmol/g, 10 mmol) was weighed and placed in a solid phase reactor, to which 150 mL of 25% PIP/DMF solution was added for deprotection, which was stirred at 25°C for 30 minutes. After the reaction was completed, the resin was washed by turns with DMF and DCM for three times. Fmoc-Pro-OH (10.1 g, 30 mmol) and HOBt (4.05 g, 30 mmol) were dissolved in 150 ml of DMF and added to the reactor. To the reaction mixture DIC (3.78 g, 30 mmol) was slowly added at 0°C to 5°C, then the deprotected amino acid resin was added, and stirred for reaction at 30°C for 3 hours. The reaction was detected for its end point by the ninhydrin method. After the reaction was completed, the resin was filtered, and washed by turns with DMF and DCM for three times. The above steps were repeated, and Fmoc-Trp-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Har-OH and Fmoc-Cys(Trt)-OH were sequentially coupled in accordance with the peptide sequence, to obtain Fmoc-Cys(Trt) -Har-Gly-Asp(OtBu)-Trp- Pro-Cys(Trt) -Wang resin, of which the degree of substitution was detected to be 0.6 mmol/g.
- Linear polypeptide 1-resin was Fmoc-D-Phe-Pro-Arg(pbf)-Pro-Gly-Gly-Gly-Gly-Asn(Trt)-Gly-Asp(OtBu)-Ile-Pro-Glu(OtBu)-Glu(OtBu)-Tyr(OtBu)-Leu-Gly-Gly-Gly-Gly-Ser(Trt)-Cys(Trt)-Har-Gly-Asp(OtBu)-Trp-Pro-Cys(Trt)-Wang.
- To 20 g of Fmoc-Cys(Trt)-Har-Gly-Asp(OtBu)-Trp-Pro-Cys(Trt)-Wang resin (degree of substitution: 0.6 mmol/g, 12 mmol), 300 ml of 25% PIP/DMF solution was added for deprotection, which was stirred at 25°C for 30 minutes. After the reaction was completed, the resin was washed by turns with DMF and DCM for three times. Fmoc-Ser(Trt)-OH (20.5 g, 36 mmol) and HOBt (4.86 g, 36 mmol) were dissolved in 150 ml of DMF and added to the reactor. To the reaction mixture DIC (4.53 g, 36 mmol) was slowly added at 0°C to 5°C, then the deprotected amino acid resin was added, and stirred for reaction at 30°C for 3 hours. The reaction was detected for its end point by the ninhydrin method. After the reaction was completed, the resin was filtered and washed by turns with DMF and DCM for three times. Fmoc-Gly-Gly-Gly-Gly-OH, Fmoc-Leu-OH, Fmoc-Tyr(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Ile-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gly-Gly-Gly-Gly-OH, Fmoc-Pro-OH, Fmoc- Arg(pbf)-OH, Fmoc-Pro-OH and Fmoc-D-Phe-OH were sequentially introduced with the above method, to obtain polypeptide 1-Wang resin in which side chains of amino acids are all protected.
- 20 g of the polypeptide 1-Wang resin in which side chains of amino acids are all protected prepared in
Step 3 was added to an acidizing agent (trifluoroacetic acid: triisopropylsilane: water = 190 ml: 5 ml: 5 ml), and reacted at 25°C for 2 hours. The resin was filtered, and washed with a small amount of trifluoroacetic acid, and the filtrate was combined. Under vigorous stirring, the filtrate was slowly added to 1.1 L precooled diethyl ether and a white precipitate appeared. After standing for 1 hour, the mixture was subjected to suction filtration, and the filter cake was washed with ice diethyl ether for 5 times and dried under vacuum to obtain 6 g of crude product. -
Polypeptide 1 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 4): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gly Gly Gly Gly Ser Cys Har Gly Asp Trp Pro Cys. 10 g of thelinear polypeptide 1 prepared instep 4 was dissolved in 200 ml pure water, and thereto a 5% I2 solution was slowly add dropwise under stirring. The reaction was detected by HPLC. After the reaction was completed, the target product was purified by high performance liquid chromatography and lyophilized to obtain thefinal product polypeptide 1 in a weight of 1 g. Detection results of mass spectrometry ofpolypeptide 1 are shown inFigure 1 . -
Polypeptide 2 was prepared in the same manner as Example 1, except that the L' fragment was Glu Ala Ala Ala Lys, to obtainpolypeptide 2 in a product weight of 1.2 g. Detection results of mass spectrometry ofpolypeptide 2 are shown inFigure 2 . -
Polypeptide 2 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 5): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Glu Ala Ala Ala Lys Cys Har Gly Asp Trp Pro Cys -
Polypeptide 3 was prepared in the same manner as Example 1, except that the fragment Gly Gly Gly Gly Ser (i.e., the fragment L') was removed to obtainpolypeptide 3 in a product weight of 1.5 g. Detection results of mass spectrometry ofpolypeptide 3 are shown inFigure 3 . -
Polypeptide 3 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 6): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Glu Ala Ala Ala Lys Cys Har Gly Asp Trp Pro Cys -
Polypeptide 4 was prepared in the same manner as Example 1, except that the L' fragment was Arg Val Leu Ala Glu Ala to obtainpolypeptide 4 in a product weight of 0.86 g. Detection results of mass spectrometry ofpolypeptide 4 are shown inFigure 4 . -
Polypeptide 4 has a structural formula as shown below (a polypeptide sequence shown in SEQ ID No. 7): D-Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Glu Ala Ala Ala Lys Cys Har Gly Asp Trp Pro Cys - Test examples 1 to 4 are used to demonstrate the anticoagulant and antiplatelet aggregation effect of
polypeptides 1 to 4 prepared in Examples 1 to 4 on human blood. 30 ml of venous blood was drawn from a healthy volunteer, quickly injected into a plastic tube containing 3 ml of 3.8% sodium citrate solution, and then gently mixed by inversion up and down. The drawn blood was centrifuged at 810 rpm for 8 minutes to obtain platelet rich plasma (PRP), which was taken out, then the blood sample was further centrifuged at 3510 rpm for 8 minutes to obtain platelet poor plasma (PPP). - 1. Determination of prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT): Reagent reconstruction and preservation were performed according to the operation requirements of the kit. For each of the PPP, 10 samples to be detected were placed into test cups respectively, and individually added with physiological saline,
polypeptide 1,polypeptide 2,polypeptide 3 orpolypeptide Table 3. Effect of polypeptides 1-4 on human blood coagulation in vitro Test samples Concentration (mol/L) PT(S) Fold of Prolongation in PT APTT(S) Fold of Prolongation in APTT TT(S) Physiological saline 0 11.22 - 31.10 - 14.07 Polypeptide 1 (n=16) 1×10-6 25.86 2.30 87.51 2.87 >180 Polypeptide 2 (n=7) 1×10-6 34.78 3.04 104.14 3.35 >180 Polypeptide 3 (n=3) 1×10-6 25.67 2.14 101.97 2.94 >180 Polypeptide 4 (n=3) 1×10-6 58.93 4.92 98.85 2.57 >180 - The results in Table 3 show that, all of the four
polypeptides 1 to 4 can affect human blood coagulation in vitro, and prolong the PT, APTT and TT to different extents. Among these compounds at a final concentration of 1×10-6 mol/L,polypeptide 2 prolonged the PT and APTT in the largest fold. - 2. Determination of platelet aggregation: A platelet aggregation instrument was started up and preheated for 30 minutes, and then calibrated with PPP. Into the test cups 270 µl of PRP was added, and then 10 µl of
polypeptide 1,polypeptide 2,polypeptide 3 or polypeptide 4 (1.0×10-7 mol/L) and/or 20 µl of physiological saline were added respectively, till a total volume of 300 µl. After incubation for 5min, 5 µl of inducer ADP and 5 µl of epinephrine were added to start the test. After 5 minutes, the test was completed, and the maximum aggregation rate within the 5 minutes was recorded, and the data and maps were printed. Based on the test results, the inhibitory rates of polypeptides 1-4 at different concentrations on platelet aggregation in human were calculated according tocalculation equation 1, and the effect of polypeptides 1-4 on the ADP-induced human platelet aggregation in vitro is listed in Table 4. Thecalculation equation 1 is as follows: - Table 4. Effect of polypeptides 1-4 on ADP-induced human platelet aggregation in vitro
Test samples Concentration (mol/L) Platelet aggregation rate (%) Inhibitory rate of platelet aggregation (%) Physiological saline - 73.39 - Polypeptide 1 (n=8) 3×10-6 39.10 47.07 Polypeptide 2 (n=7) 3×10-6 26.12 66.70 Polypeptide 3 (n=3) 3×10-6 57.85 26.35 Polypeptide 4 (n=3) 3×10-6 61.28 18.88 Polypeptide 1 (n=8) 1×10-5 4.90 92.04 Polypeptide 2 (n=7) 1×10-5 0 100 Polypeptide 3 (n=3) 1×10-5 35.40 47.07 Polypeptide 4 (n=3) 1×10-5 54.80 27.97 - The results in Table 4 show that, all of the four compounds,
polypeptide 1,polypeptide 2,polypeptide 3 andpolypeptide 4, can affect ADP-induced human platelet aggregation in vitro. Integrilin at a final concentration of 3×10-6 mol/L can completely inhibit ADP-induced human platelet aggregation in vitro, with an inhibitory rate of 100%, and among the four compounds,polypeptide 1,polypeptide 2,polypeptide 3,polypeptide 4, at final concentrations of 3×10-6 mol/L and 1×10-5 mol/L,polypeptide 2 showed a strongest inhibition on ADP-induced human platelet aggregation in vitro. - This test example is used to demonstrate the antithrombotic effect of
polypeptide 2 prepared in EXAMPLE 2 in rats. - 1. Experimental animals: 160 healthy, adult male SD rats, with body weight of 250 g ∼ 300 g, purchased from Beijing Vital River Co., Ltd. Animal production license number: SCXK (Beijing) 2012-0001.
- 2. Samples to be tested:
polypeptide 2 with a peptide content of 97.21%. Enoxaparin Sodium Injection, Aventis Intercontinental, Sanofi (Beijing) Pharmaceutical Co., Ltd., Subpackaging Approval Number: State medicine approval number: J20090094. Lot number: 2SN76, 0.4 ml: 4000 AxaIU × 2 vials. Bivalirudin for Injection, Xi'an Xintong Pharmaceutical Research Co., Ltd., with a molecular weight of 2180.2, a purity of 96.55%, and a content of 69.44%. -
- 3.1.1.1 Formulation of
polypeptide 2 test solution: 200 mg ofpolypeptide 2 was accurately weighed and 10 mg/mL stock solution was prepared with physiological saline. An appropriate amount of the stock solution was taken to formulate the required dose according to the body weight of the animals, before the experiment every day. - 3.1.1.2 Formulation of 20% urethane solution: 20 g of urethane was accurately weighed and metered with distilled water to a volume of 100 ml.
- 3.1.1.3 Formulation of 3.8% sodium citrate solution: 4.33g of sodium citrate dihydrate was accurately weighed and metered with physiological saline to a volume of 100 ml, to obtain a 3.8% solution for use.
-
- 3.1.2.1 Aluminum foil: The foil was measured with a ruler and cut to 2.5 cm × 2.5 cm, numbered and weighed.
- 3.1.2.2 Preparation of 35% ferric chloride solution: 35 g of ferric chloride was taken and dissolved in 100 mL distilled water.
- 160 Rats were randomly divided into groups, 5 to 10 rats per group. 1) Model control group: intravenous injection of the same volume of physiological saline; 2) 6 dose groups of polypeptide 2: starting from 1.5 mg/kg+3.75 mg/kg/h, which was decreased to 1 mg/kg+2.5 mg/kg/h, 0.5 mg/kg+1.25 mg/kg/h, 0.25 mg/kg+0.75 mg/kg/h, 0.125 mg/kg+0.375 mg/kg/h, and 0.041 mg/kg+0.125 mg/kg/h; 3) 5 dose groups of positive control enoxaparin: starting from 30 U/kg+45 U/kg/h, which was increased to 60 U/kg+60 U/kg/h, 30 U/kg+120 U/kg/h , 90 U/kg+120 U/kg/h, 60 U/kg +240 U/kg/h, 4) 5 dose groups of positive control bivalirudin: starting from 0.5 mg/kg+2 mg/kg/h, which was decreased to 0.35 mg/kg+1.3 mg/kg/h, 0.17 mg/kg+0.65 mg/kg/h, 0.08 mg/kg+0.325 mg/kg/h. The animals were fasted with access to water 12 hours before the experiment (as shown in Table 5).
- According to the body weight in kilograms of the rats, the first dose of a drug was dissolved in 2 mL of physiological saline for single bolus injection. The maintaining dose of drug was dissolved in 9 ml of physiological saline, and placed in a double-channel micro-injection pump, which was dripped off within 90 minutes at a dripping speed of 0.1 ml/min. The sham operation group was administered with the same volume of physiological saline.
- The rats were fasted with free access to water overnight before the experiment. The rats were anesthetized with intravenous injection of a 20% urethane solution at 5 ml/kg, fixed in the supine position, and then, the bilateral common carotid arteries, external jugular veins and inferior vena cava were isolated. The external jugular vein was subjected to intubation for administration; the common carotid artery on one side was subjected to intubation for blood collection to determine the blood coagulation functions PT and APTT, and the common carotid artery on the other side was used for the establishment of an arterial thrombosis model; and the inferior vena cava was used for the establishment of a venous thrombosis model.
- The blood samples were taken before administration, administration for 60 minutes, and before termination of administration, respectively, to determine their activated partial thromboplastin time (APTT) and prothrombin time (PT). The blood samples were centrifuged at 3510 rpm for 8 minutes to obtain platelet poor plasma (PPP). Reagent reconstruction and preservation were performed according to the operation requirements of the kit. Immediately after each blood sample was placed into a test cup and then PT and APTT reagents were added, the test was started. After the test was completed, results were recorded.
- After administration at a load dosage maintenance for 30 minutes, a filter paper with a 3 mm diameter and immersed with 35% FeCl3 solution was applied below the common carotid artery, below which a small piece of a plastic film (2.5 cm × 2.0 cm) was placed to protect surrounding tissues. The body temperature was detected with a temperature probe in the distal end of the artery, and the time required from the beginning of stimulation to the point when the temperature decreased by 2.5 degrees was examined as the vascular occlusion time.
- After administration at a load dosage maintenance for 30 minutes, a filter paper with a 3 mm diameter and immersed with 35% FeCl3 solution was applied below the inferior vena cava, below which a small piece of a plastic film (2.5 cm × 2.0 cm) was placed to protect surrounding tissues. 15 minutes later, the filter paper was removed. And then, after observation for 45 minutes, the blood vessels and local tissues were rinsed with warm physiological saline, and the covered blood vessels were cut off. The thrombus which attached to the blood vessel walls was peeled off to be weighed on a tin foil for its wet weight, and then weighed overnight at room temperature for its dry weight. The administration was continued until the completion of the experiment.
- 5.1 Determination of blood coagulation function: The blood samples were taken 0 min before administration, administration for 60 minutes, and termination of administration, respectively, and then determined using a platelet-aggregation coagulation factor analyzer for the blood coagulation functions (PT, APTT) and ACT.
- The time from the point when FeCl3 was placed to the point when the temperature of the artery indicated a decrease of 2.5°C was the vascular occlusion time, which reflected the state of thrombus formation.
- After the experiment was completed, the segment of the blood vessels in which there had been thrombus formation was cut off, weighed for the wet weight, and then weighed overnight at room temperature for the dry weight of the thrombus. Thrombosis inhibitory rate was calculated.
Table 5. Dose grouping of polypeptide 2 and control drugsNo. Group Dose (mg/kg+mg/kg/h) n 1 Model -- 10 2 Enoxaparin group 130+ 45u 6 3 Enoxaparin group 260+ 60u 5 4 Enoxaparin group 330+ 120u 5 5 Enoxaparin group 490+ 120u 6 6 Enoxaparin group 560+ 240u 10 7 Bivalirudin group 10.08+0.325 6 8 Bivalirudin group 20.17+0.65 6 9 Bivalirudin group 30.35+1.3 8 10 Bivalirudin group 40.5+2 5 11 Polypeptide 2group 10.041+0.125 10 12 Polypeptide 2group 20.125+0.375 10 13 Polypeptide 2group 30.25+0.75 9 14 Polypeptide 2group 40.5+1.25 10 15 Polypeptide 2group 51+2.5 9 16 Polypeptide 2group 61.5+3.75 10 Table 6. Effect of intravenous maintenance administration of polypeptide 2 and control drugs at different dosages on FeCl3-induced thrombosis in rats (x ±s)No. Inferior vena cava thrombosis Common carotid arterial thrombosis Thrombus weight (mg) Inhibition percentage (%) OT (min) Fold of prolongation 1 22.54±2.60 - 22.54±2.60 - 2 14.67±8.44* 34.93 48.17±13.12** 1.93±0.52 3 11.18±4.47** 50.42 55.75±7.23** 2.23±0.29 4 11.48±2.81** 49.07 41.4±6.68** 1.66±0.27 5 8.10±3.67** 64.06 48.83±11.58** 1.95±0.46 6 6.59±2.54** 86.25 49.75±5.04** 1.99±0.20 7 18.03±1.39* 20.03 44.75±1.53** 1.79±0.06 8 14.43±3.84** 35.97 56.00±6.03** 2.24±0.24 9 7.06±4.07** 68.67 55.63±8.21** 2.23±0.33 10 7.26±3.15** 67.79 58.00±5.77** 2.32±0.23 11 20.20±10.00 10.38 20.20±10.00 10.38 12 16.23±6.76* 27.99 16.23±6.76* 27.99 13 14.23±4.82** 36.85 14.23±4.82** 36.85 14 9.25±4.86** 58.96 9.25±4.86** 58.96 15 9.91±6.20** 56.03 9.91±6.20** 56.03 16 7.13±3.46** 68.37 7.13±3.46** 68.37 Table 7. Effect of intravenous maintenance administration of polypeptide 2 and control drugs at different dosages on blood coagulation function in rats ( x ±s)Group Dose n APTT Before administration administration for 60 minutes Fold of change Model - 10 28±6.18 29.54±6.58 1.18±0.51 Enoxaparin group 1 30+45u 6 28.99±7.00 52.28±22.51 1.78±0.61 Enoxaparin group 2 60+60u 5 23.45±4.70 61.81±13.19 2.66±0.36 Enoxaparin group 3 30+120u 5 23.66±5.88 117.55±78.85 4.65±1.72 Enoxaparin group 4 90+120u 6 19.04±5.26 270.85±148.90 16.34±12.97 Enoxaparin group 5 60+240u 10 26.79±4.74 270.43±166.43 10.69±7.14 Bivalirudin group 1 0.08+0.325 6 25.05±1.78 34.18±12.92 1.36±0.50 Bivalirudin group 2 0.17+0.65 6 25.55±5.02 41.46±14.96 1.66±0.60 Bivalirudin group 3 0.35+1.3 8 23.16±2.37 95.86±45.71 4.10±1.86 Bivalirudin group 4 0.5+2 5 24.77±7.84 90.23±21.92 3.89±1.37 Polypeptide 2 group 1 0.041+0.125 10 24.54±5.09 37.29±10.59 1.65±0.84 Polypeptide 2 group 2 0.125+0.375 10 24.05±5.44 44.55±12.74 1.94±0.68 Polypeptide 2 group 3 0.25+0.75 9 24.98±5.11 53.13±22.57 2.22±1.12 Polypeptide 2 group 4 0.5+1.25 10 22.03±4.70 52.29±25.87 2.49±1.38 Polypeptide 2 group 5 1+2.5 9 23.98±6.83 108.52±56.27 5.01±3.00 Polypeptide 2 group 6 1.5+3.75 10 23.94±4.49 74.62±49.41 3.19±2.02 Group Dose n PT Before administration administration for 60 minutes Fold of change Model - 10 11.38±3.00 12.32±1.59 1.08±0.40 Enoxaparin group 1 30+45u 6 10.23±1.19 12.70±2.49 1.24±0.14 Enoxaparin group 2 60+60u 5 9.53±1.96 31.39±35.50 4.10±5.56 Enoxaparin group 3 30+120u 5 9.93±1.77 16.17±1.86 1.67±0.42 Enoxaparin group 4 90+120u 6 9.63±1.58 14.88±1.67 1.57±0.21 Enoxaparin group 5 60+240u 10 10.28±0.98 18.21±2.70 1.78±0.30 Bivalirudin group 1 0.08+0.325 6 10.42±1.16 18.95±3.36 1.82±0.24 Bivalirudin group 2 0.17+0.65 6 11.16±1.28 21.85±7.38 1.99±0.78 Bivalirudin group 3 0.35+1.3 8 11.73±1.48 42.58±21.94 3.54±1.45 Bivalirudin group 4 0.5+2 5 7.87±1.93 39.13±7.30 4.46±1.47 Polypeptide 2 group 1 0.041+0.125 10 10.74±3.97 18.95±8.65 1.95±1.27 Polypeptide 2 group 2 0.125+0.375 10 11.21±1.62 19.00±4.39 1.70±0.34 Polypeptide 2 group 3 0.25+0.75 9 11.19±1.06 20.82±5.66 1.87±0.50 Polypeptide 2 group 4 0.5+1.25 10 10.58±1.48 26.07±3.91 2.53±0.73 Polypeptide 2 group 5 1+2.5 9 10.53±1.29 56.65±23.16 5.57±2.74 Polypeptide 2 group 6 1.5+3.75 10 11.98±1.02 46.64±23.46 3.91±1.89 - As can be seen from the results of Tables 6 and 7,
polypeptide 2 can dose-dependently inhibit FeCl3-induced inferior vena cava thrombosis in rats, inhibit FeCl3-induced common carotid arterial thrombosis in rats, and prolong APTT and PT in rats. -
Figure 5 shows effect ofpolypeptide 2 on FeCl3-induced inferior vena cava thrombosis in rats, with *P<0.05, **P<0.01 compared with the model group.Figure 6 shows effect ofpolypeptide 2 on FeCl3-induced common carotid arterial thrombosis in rats, which shows the fold of change in the arterial occlusion time, with *P<0.05, **P<0.01 compared with the model group.Figure 7 shows effect ofpolypeptide 2 on APTT in rats.Figure 8 shows effect ofpolypeptide 2 on PT in rats. - This test example is used to illustrate a pharmacodynamic test of thrombus inhibition in rabbits by intravenous maintenance administration of
polypeptide 2 prepared in EXAMPLE 2. -
1.1 Experimental animals: 10 healthy adult male rabbits, weighed to be 2 to 2.5 kg, provided by Xi'an Dilepu Biological Resources Development Co., Ltd.. Animal production license number: SCXK (Shaanxi) 2006-001. Samples to be tested:polypeptide 2 having a peptide content of 97.21%. Positive control: Enoxaparin Sodium Injection, Aventis Intercontinental, Sanofi (Beijing) Pharmaceutical Co., Ltd., Subpackaging Approval Number: state medicine approval number: J20090094. Lot number: 2SN76, 0.4 ml: 4000 AxalU × 2 vials.
1.2 Experimental materials are shown in Table 8.Table 8 Name Manufacturer Specification Lot No. Sodium pentobarbital US sigma Company 25 g/bottle 090205 Sodium citrate Tianjin Baishi Chemical Co., Ltd. - 20080418 0.9%NaCl injection Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd. 250 mL/bottle 11806471 Heparin sodium injection Tianjin Biochemical Pharmaceutical Co., Ltd. 2mL 12500IM 20120202 Diadenosine phosphate SIGMA 1g/bottle purchased on December 10, 2009 Adrenal hydrochloride injection Shanghai Hefeng Pharmaceutical Co. Ltd. 1mg/mL 20090701 PT Assay Kit Shaanxi Ark Biotechnology Co., Ltd. 10×2ml 20140703 TT Assay Kit Shaanxi Ark Biotechnology Co., Ltd. 10×2ml 20140702 APPT Assay Kit Shaanxi Ark Biotechnology Co., Ltd. 10×2ml 20140702
1.3 Formulation ofpolypeptide 2 test solution: 200 mg ofpolypeptide 2 was accurately weighed with an electronic balance and was prepared into 10 mg/mL stock solution with physiological saline, which was sufficiently mixed well, sub-packaged in 5 mL for each, and stored at -20°C. During the test, an appropriate amount of the stock solution was diluted and used by calculation based on the body weight of the rabbits.
3% Sodium pentobarbital solution: 3 g of sodium pentobarbital was accurately weighed and metered with distilled water to a volume of 100 ml.
3.8% Sodium citrate solution: 4.33g of sodium citrate dihydrate was accurately weighed and metered with physiological saline to a volume of 100 ml, to obtain a 3.8% solution for use.
Epinephrine solution: 1.319 ml of stock solution was taken and metered to 100 ml with physiological saline to prepare a 60 µM solution, which was stored at 4°C in a refrigerator and sub-packaged before use.
ADP solution: 14.3 mg of ADP was accurately weighed and dissolved in 5 ml of physiological saline to obtain a 6000 µmol/L ADP solution which was stored at 4°C, and was diluted with physiological saline to 600 µmol/L before the experiment.
1.4 Preparation of materials
Aluminum foil: The foil was measured with a ruler and cut to 2.5 cm × 2.5 cm, numbered and weighed; nonabsorbable surgical suture: 8 cm long of the suture was taken with a ruler and weighed.
50% ferric chloride solution: 50 g of ferric chloride was taken and dissolved in 100 mL of distilled water. - 2. Grouping and administration: 10 rabbits were randomly divided into 3 groups, 2 to 3 rabbits per group. 1) Sham operation group (NS): Intravenous injection of the same volume of physiological saline, with the same operation method as above; 2)
polypeptide 2 administration group: 8.0mg/kg+20.0 mg/kg/h; 3) positive control enoxaparin group: 50 U/kg+150 U/kg/h. According to the body weight in kilograms of the rabbits, the first dose of the drug to be tested was dissolved in 2 mL of physiological saline for single bolus injection. The maintaining dose was dissolved in 9 ml of physiological saline, and placed in a double-channel micro-injection pump, which was dripped off within 90 minutes at a dripping speed of 1 ml/min. The sham operation group was administered with the same volume of physiological saline. -
- 3.1 Surgery preparation of rabbits: Rabbits were sent to the laboratory for accommodation for one day, and then screened at first. Blood samples were taken from arteries within ears, which were subjected to blood routine analysis and APTT assay, and the rabbits with normal blood hemateikon and APTT between 16s to 28s were selected for experiments. The rabbits to be tested were fasted with free access to water for the night before the experiment. The rabbits were anesthetized with intravenous injection of 3% sodium pentobarbital solution at 1 ml/kg, fixed in the supine position, and then, the common carotid artery at one side, external jugular vein, femoral artery at one side, femoral vein, and forelimb vein at one side were isolated. The forelimb vein was subjected to intubation for administration; the left femoral vein was subjected to intubation for blood collection to determine the platelet aggregation rate; the femoral artery was used for the establishment of an arterial thrombosis model; the common carotid artery and external jugular vein were used for the establishment of an arterial and venous bypass thrombosis model.
- 3.2 Arterial thrombosis (AT) model: A small piece of a filter paper (1 cm × 1.5 cm) absorbed with 50% FeCl3 solution was applied onto the right femoral artery while administration, below which a small piece of a plastic film (2.5 cm × 2.0 cm) was placed to protect surrounding tissues. After 10 minutes, the filter paper was removed, and then, the blood vessels and local tissues were rinsed with warm physiological saline, and the covered blood vessels were cut off. The thrombus which attached to the blood vessel walls was peeled off to be weighed on a tin foil for its wet weight, and then kept overnight at room temperature and weighed for its dry weight.
- 3.3 Experimental Procedures: The femoral arteries in the forelimb and both sides in the rabbits were isolated and stabilized for 10 minutes before the administration was started. An AT model was established by covering the femoral artery with a 50% FeCl3 filter paper while administration, and the filter paper was removed after 15 minutes. Observation was continued for 120 min after administration until the experiment was completed.
-
- 4.1 Platelet aggregation rate: At points of 0 min before administration; 30 min, 60 min, 90 min for administration; 60 min, 120 min, 180 min after administration was terminated, 2.7 ml blood samples were taken from the femoral vein, rapidly injected into a centrifuge tube containing 0.3 ml of 3.8% sodium citrate solution, and fully mixed well. The resulted blood samples were centrifuged at 810 rpm (100 g) for 8 min to obtain PRP, and was centrifuged at 3500 rpm (1863 g) for 8 min to obtain PPP which was used to determine platelet aggregation.
Blood samples were taken before administration (0 min), 5 min and 15 min after administration, respectively, to determine the platelet aggregation rate which was used to calculate the inhibitory rate of platelet aggregation with a calculation equation as follows: - 4.2 Determination of blood coagulation function: Blood samples were taken and the blood function (PT, APTT) was determined at 0 min before administration, at points of 30 min, 60 min, 90 min after administration, and at points of 60 min, 120 min and 180 min after termination of administration, using a platelet-aggregation coagulation factor analyzer. Blood samples were centrifuged at 3510 rpm for 8 min to obtain platelet poor plasma (PPP). Reagent reconstruction and preservation were performed according to the operation requirements of the kit. Immediately after each blood sample was placed into a test cup and then added with PT, TT and APTT reagents, the test was started. After the test was completed, results were recorded.
- 4.3 Determination of ACT: At 0 min before administration and at points of administration for 5 min and 15 min, the whole blood was taken, to which kaolin was added, and placed in a water bath at 37°C to record the whole blood coagulation time.
- 4.4 Thrombus weight: After the experiment was completed, the segment of the blood vessels in which there had been thrombus formation was cut off, weighed for the wet weight, and then kept overnight at room temperature and weighed for the dry weight. The thrombosis inhibitory rate was calculated with a calculation equation as follows:
- The results show the effect of
polypeptide 2 at 8.0 mg/kg+20.0 mg/kg/h on FeCl3-induced femoral artery thrombosis in rabbits, in which the thrombosis inhibitory rate of enoxaparin at 50 U/kg+150 U/kg/h is lower than that ofpolypeptide 2, which has no statistic difference (P>0.05) compared with the physiological saline group. The results are shown in Table 9.Table 9. Effect of intravenous maintenance administration of polypeptide 2 on femoral artery thrombosis in rabbits (x ±s)Group Dose (mg/kg+ mg/kg/h) n Thrombus weight (mg) Thrombus inhibitory rate (%) Wet weight Dry weight Wet weight Dry weight Blank group - 3 58.2±11.2 20.9±5.9 - - Enoxaparin 50U+ 150U 2 3.9±4.0 2.3±2.1 40±5.7 10±4.2 Polypeptide 2 8.0+20.0 4 14.2±10.2 3.2±2.0* 75.6±3.8 84.9±2.3 - The results show that, the intravenous maintenance administration of
polypeptide 2 can inhibit platelet aggregation in rabbits. After the administration was terminated, the inhibition of platelet aggregation was gradually weakened over time. The inhibitory rate of platelet aggregation by enoxaparin at 50 U/kg+150 U/kg/h is lower than that ofpolypeptide 2. The results are shown in Table 10.Table 10. Effect of single intravenous administration of polypeptide 2 on platelet aggregation function in rabbits (inhibitory rate of platelet aggregation, %,x ±s)Group Dose (mg/kg+ mg/kg/h) n Administration for 30 min Administration for 60 min Administration for 90 min Blank group - 2 12.1±17.1 12.1±17.1 13.1±18.6 Enoxaparin 50U+ 150U 1 26.7 0.00 35.27 Polypeptide 2 8.0+20.0 2 61.0±14.1 72.1±9.6 55.8±7.7 Group Dose (mg/kg+ mg/kg/h) n 60 min after termination 120 min after termination 180 min after termination Blank group - 2 22.1±31.2 13.9±19.7 - Enoxaparin 50U+ 150U 1 0.00 41.9 - Polypeptide 28.0+20.0 2 14.1±1.5 7.5±1.8 47.5±2.5 - The results are shown in Tables 11-14. Table 11 shows the effect of intravenous maintenance administration of
polypeptide 2 on the blood coagulation function APTT in rabbits (S, (x ±s)); Table 12 shows the effect of intravenous maintenance administration ofpolypeptide 2 on the blood coagulation function PT in rabbits (S, (x ±s)); Table 13 shows the effect of intravenous maintenance administration ofpolypeptide 2 on the blood coagulation function TT in rabbits (S, (x ±s)); and Table 14 shows the effect of intravenous maintenance administration ofpolypeptide 2 on ACT in rabbits (S, (x ±s)). In Tables 11-14, the dose unit is (mg/kg+mg/kg/h). The results show that the intravenous maintenance administration ofpolypeptide 2 can inhibit platelet aggregation in rabbits. After the administration was terminated, the inhibition of platelet aggregation was gradually weakened over time.Table 11 Group Dose n Before administration Administration (min) Termination (min) 30 60 90 60 120 180 Blank - 2 24.3±4.4 22.7±1.6 20.4±1.9 20.2±0.4 19.9±1.0 35.0±8.3 ± Enoxaparin 50U+150U 1 25.7 32.4 36.2 38.3 30.5 62.1 41.6 Polypeptide 2 8.0+20.0 2 22.7±1.7 38.0±2.3 32.5±1.0 34.1±3.7 35.7±14.0 33.2±2.7 23.3±1.6 Table 12 Group Dose n Before administration Administration (min) Termination (min) 30 60 90 60 120 180 Blank - 2 6.3±0.8 7.0±1.4 6.3±2.5 6.1±1.8 5.7±0.6 5.9±0.5 ± Enoxaparin 50U+150U 1 9.4 10.4 10.4 11.3 8.2 8.1 7.6 Polypeptide 2 8.0+20.0 2 7.7±1.8 12.7±0.5 9.4±2.0 11.6± 1.3 7.7±0.0 7.1±1.8 7.4±1.3 Table 13 Group Dose n Before administration Administration (min) Termination (min) 30 60 90 60 120 180 Blank - 2 21.1±4.9 18.3±2.4 17.3±3.0 17.7±2.7 15.6±0.0 17.7±2.1 ± Enoxaparin 50U+150U 1 20.5 >180s >180s 18.9 21.0 29.0 24.0 Polypeptide 2 8.0+20.0 2 26.8±15.5 >180s >180s >180s >180s 150.6±3.5 28.2±1.9 Table 14 Group Dose n Before administration Administration (min) Termination (min) 30 60 90 60 120 180 Blank - 2 210.0±21.2 180.0±21.2 127.5±31.8 127.5±10.6 112.5±74.2 165.0±21.2 ± Enoxaparin 50U+150U 1 180.0 225.0 375.0 270.0 210 195.0 225.0 Polypeptide 2 8.0+20.0 2 217.5±95.5 330.0±63.6 277.5±31.8 300.0±63.6 180.0±21.2 172.5±31.8 112.5±74.2 - The above results show that, bolus injection (iv) + intravenous drip (vd) of
polypeptide 2 for 90 minutes can inhibit platelet aggregation in rabbits, affect the blood coagulation function in rabbits, prolong APTT, PT, TT and ACT, and also inhibit femoral artery thrombosis. Whenpolypeptide 2 and enoxaparin have the comparable effect to inhibit femoral artery thrombosis and to inhibit platelet aggregation, enoxaparin prolongs APTT more thanpolypeptide 2, indicating that the bleeding risk of enoxaparin is greater than that ofpolypeptide 2. - This test example is used to illustrate antithrombotic as well as anticoagulant and antiplatelet aggregation experiments in vivo with single intravenous administration in rabbits. Experimental animals: 48 healthy adult male rabbits, weighed to be 2 to 2.5 kg, provided by Xi'an Dilepu Biological Resources Development Co., Ltd., Animal production license number: SCXK (Shaanxi) 2006-001. Samples to be tested:
polypeptide 2 having a peptide content of 97.21%. Positive drugs: enoxaparin and bivalirudin. - 1. Grouping and administration: 48 Rabbits were randomly divided into 6 groups, 8 rabbits per group. 1) Sham operation group (NS): Intravenous injection of the same volume of physiological saline; 2) positive control bivalirudin group (6 mg/kg); 3) positive control enoxaparin group (200 U/kg); 4) Low dose group of polypeptide 2 (3.0 mg/kg); 5) Medium dose group of polypeptide 2 (6.0 mg/kg); 6) High dose group of polypeptide 2 (12.0 mg/kg).
Polypeptide 2 was administered by single intravenous administration. According to the body weight in kilograms of the rabbits, the sample was dissolved in 2 mL of physiological saline for single bolus injection. The sham operation group was administered with the same volume of physiological saline. -
- 2.1 Surgery preparation of rabbits: Rabbit were sent to the laboratory for accommodation for one day, and then screened at first. Blood samples were taken from arteries within ears, which were subjected to blood routine analysis and APTT examinations, and the rabbits with a normal blood hemogram and APTT between 16 and 28 seconds were selected for experiments. The rabbits to be tested were fasted with free access to water in the night before the experiment. The rabbits were anesthetized with intravenous injection of 3% sodium pentobarbital solution at 1 ml/kg, fixed in the supine position, and then, the common carotid artery at one side, external jugular vein, femoral artery at one side, femoral vein, and forelimb vein at one side were isolated. The forelimb vein was subjected to intubation for administration; the left femoral vein was subjected to intubation for blood collection to determine the platelet aggregation rate; the femoral artery was used for the establishment of an arterial thrombosis model; the common carotid artery and external jugular vein were used for the establishment of an arterial and venous bypass thrombosis model.
- 2.2 Arterial and venous bypass thrombosis (AVST) model: An arterial and venous shunt consists of two casings, of which an outer casing has a length of about 8 cm and an inner diameter of 7.9 mm, the inner casing has a length of about 2.5 cm and an inner diameter of 4.8 mm. The polyethylene tube was charged with a silk thread about 8 cm long and filled with 50 M/ml heparin solution, of which one end was inserted into the left femoral artery and the other end was inserted into the right femoral vein. After administration for 30 seconds, the blood flow was released, which flowed from the left artery to the polyethylene tube and returned to the right vein. After 15 minutes, the blood flow was interrupted, the silk thread was quickly removed and placed on an aluminum foil (size: 2.5 cm × 2.5 cm), measured for its wet weight, and kept overnight at room temperature and weighed for its dry weight.
- 2.3 Arterial thrombosis (AT) model: A small piece of filter paper (1 cm × 1.5 cm) absorbed with 50% FeCl3 solution was applied onto the right femoral artery while administration, below which a small piece of a plastic film (2.5 cm × 2.0 cm) was placed to protect surrounding tissues. After 10 minutes, the filter paper was removed, and then, the blood vessels and local tissues were rinsed with warm physiological saline, and the covered blood vessels were cut off. The thrombus which attached to the blood vessel walls was peeled off to be weighed on a tin foil for its wet weight, and then kept overnight at room temperature and weighed for its dry weight.
- 2.4 Experimental Procedures: Experimental procedures are shown in
Figure 9 . The femoral arteries in the forelimb and both sides in the rabbits were isolated and stabilized for 10 min before the administration was started. An AT model was established by covering the femoral artery with 50% FeCl3 filter paper while administration, and the filter paper was removed after covering for 15 minutes. An AVST model was established and it was taken out after 40 minutes. Observation was continued for 120 min after administration until the experiment was completed. -
- 3.1 Platelet aggregation rate: 2.7 ml of blood was taken from the femoral vein, rapidly injected into a centrifuge tube containing 0.3ml of 3.8% sodium citrate solution, and fully mixed well. The resulted blood samples were centrifuged at 810 rpm (100 g) for 8 min to obtain PRP, which was taken out and centrifuged at 3500 rpm (1863 g) for 8 min to obtain PPP, which was used to determine platelet aggregation.
Blood samples were taken at a point before administration (0 min), and at points of administration for 5 min and 15 min, respectively, to determine the platelet aggregation rate, which was used to calculate the inhibitory rate of platelet aggregation with a calculation equation as follows: - 3.2 Determination of blood coagulation function: Blood samples were taken and the blood function (PT, TT, APTT) was determined at 0 min before administration, at points of 5 min and 15 min after administration, using a platelet-aggregation coagulation factor analyzer. Blood samples were centrifuged at 3510 rpm for 8 min to obtain platelet poor plasma (PPP). Reagent reconstruction and preservation were performed according to the operation requirements of the kit. Immediately after each blood sample was placed into a test cup and then added with PT, TT and APTT reagents, the test was started. After the test was completed, results were recorded.
- 3.3 Determination of ACT: At 0 min before administration and at points of administration for 5 min and 15 min, the whole blood was taken, to which kaolin was added, and placed in a water bath at 37°C to record the whole blood coagulation time.
- 3.4 Thrombus weight: After the experiment was completed, the segment of the blood vessels in which there had been thrombus formation was cut off, weighed for the wet weight, and then kept overnight at room temperature and weighed for the dry weight. The thrombosis inhibitory rate was calculated with a calculation equation as follows:
- The results are shown in
Figure 10 and Table 15. Single intravenous administration of different concentrations ofpolypeptide 2 can reduce the dry weight of FeCl3-induced femoral artery thrombus in rabbits and inhibit FeCl3-induced femoral artery thrombosis in rabbits. Compared with the physiological saline group, there was a significant statistic difference (P<0.05) for the low dose group ofpolypeptide 2 in 3.0 mg/kg (P<0.05); there was a very significant statistic difference for the medium dose group ofpolypeptide 2 in 6.0 mg/kg and the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.01); and the effect of anti-arterial thrombosis in the medium dose group ofpolypeptide 2 was better than that of the bivalirudin group.Table 15. Effect of single intravenous administration of polypeptide 2 on FeCl3-induced femoral artery thrombosis in rabbits (x ±s)Group Dose (mg/kg) n Thrombus dry weight (mg) Thrombus inhibitory rate (%) Physiological saline group - 8 2.9±1.9 - Bivalirudin 6.0 8 1.5±0.9 * 48.20 Enoxaparin 200U 7 1.5±0.4 * 48.26 Polypeptide 2, low dose 3.0 6 1.4±0.5 * 52.99 Polypeptide 2, medium dose 6.0 8 1.2±0.7 ** 56.90 Polypeptide 2, high dose 12.0 8 1.1±0.9 ** 60.82 Compared with the physiological saline group, *P<0.05, **P<0.01. - As shown in
Figure 11 and Table 16, single intravenous administration of different concentrations ofpolypeptide 2 can reduce the dry weight of thrombus in femoral arterial and venous bypass in rabbits and inhibit femoral and venous bypass thrombosis in rabbits. Compared with the physiological saline group, there was a very significant statistic difference for the medium dose group ofpolypeptide 2 in 6.0 mg/kg and the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.01), and the effect of anti-arterial and venous bypass thrombosis in the medium dose group ofpolypeptide 2 was significantly better than that in the bivalirudin and enoxaparin groups.Table 16. Effect of single intravenous administration of polypeptide 2 for 15 min on femoral arterial and venous bypass thrombosis in rabbits (x ±s)Group Dose (mg/kg) n Thrombus dry weight (mg) Thrombus inhibitory rate (%) Physiological saline group - 8 23.6±7.0 - Bivalirudin 6.0 8 20.8±6.3 11.86 Enoxaparin 200U 7 17.3±6.5 26.88 Polypeptide 2, low dose3.0 6 20.2±4.3 14.48 Polypeptide 2, medium dose6.0 8 13.5±5.3** 42.80 Polypeptide 2, high dose 12.0 8 10.6±6.8** 55.24 Compared with the physiological saline group, *P<0.05, **P<0.01. - The results are shown in
Figure 12 and Table 17, which indicates that single intravenous administration ofpolypeptide 2 in each dose group can inhibit platelet aggregation in rabbits. After the administration was terminated, the inhibition on platelet aggregation was gradually weakened over time. - The single intravenous administration of
polypeptide 2 in each dose group for 5 min can inhibit platelet aggregation in rabbits to different extents. Compared with the physiological saline group, there was a significant statistic difference for the medium dose group ofpolypeptide 2 in 6.0 mg/kg and the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.05); and the antiplatelet effect in the medium dose group ofpolypeptide 2 was significantly better than that in the bivalirudin and enoxaparin groups. For the point of administration for 15 min, the inhibition on platelet aggregation in rabbits was gradually weakened. Compared with the physiological saline group, there was a significant difference for the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.05).Table 17. Effect of single intravenous administration of polypeptide 2 on platelet aggregation function in rabbits (inhibitory rate of platelet aggregation, %,x ±s)Group Dose (mg/kg) n Administration for 5 min Administration for 15 min Physiological saline - 8 0.6±5.8 3.2±6.0 Bivalirudin 6.0 8 5.2±5.8 4.6±6.0 Enoxaparin 200 7 9.5±6.2 16.1±6.5 Polypeptide 2, low dose 3.0 6 17.2±6.7 6.3±7.0 Polypeptide 2, medium dose 6.0 8 47.5±5.8*#¥& 15.4±6.0 Polypeptide 2, high dose 12.0 7 72.5±6.2*#¥&@ 46.0±6.5*#¥&@ Compared with the physiological saline group, *P<0.05; compared with the bivalirudin group, #P<0.05; compared with the enoxaparin group, ¥ P<0.05; compared with the low dose group of polypeptide 2, &P<0.05; compared with the medium dose group ofpolypeptide 2, @ P<0.05 - The results show that, the administration of
polypeptide 2 can prolong APTT, PT, TT and ACT in rabbits. After the administration was terminated, the prolongation of the above blood coagulation indicators was gradually weakened over time. - The results are shown in
Figure 13 and Tables 18 and 19. In each dose group ofpolypeptide 2, the APTT in rabbits can be prolonged to different extents. The prolongation of APTT was gradually weakened over time within 15 min. After administration for 5 min, compared with the physiological saline group, there was a significant statistic difference for the medium dose group ofpolypeptide 2 in 6.0 mg/kg and the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.05); and after administration for 15 min, compared with the physiological saline group, there was a significant statistic difference for the medium dose group ofpolypeptide 2 in 6.0 mg/kg and the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.05).Table 18. Effect of single intravenous administration of polypeptide 2 on APTT in rabbits (s, x±Sc)Group Dose (mg/kg) n Before administration Administration for 5 min Administration for 15 min Physiological saline - 8 23.5±1.0 23.9±3.6 21.8±2.7 Bivalirudin 6.0 8 21.6±1.0 50.4±3.6* 30.9±2.7 Enoxaparin 200 7 22.5±1.1 48.7±3.9* 40.9+2.9* Polypeptide 2, low dose3.0 6 20.6±1.2 24.4±4.2#¥ 20.0±3.1# Polypeptide 2, medium dose 6.0 8 24.1±1.0 50.5±3.6*& 34.9±2.7*& Polypeptide 2, high dose 12.0 8 23.3±1.0 54.4±3.6*& 37.0±2.7*& Compared with the physiological saline group, *P<0.05; compared with the bivalirudin group, #P<0.05; compared with the enoxaparin group, ¥ P<0.05; compared with the low dose group of polypeptide 2, &P<0.05.Table 19. Effect of single intravenous administration of polypeptide 2 on APTT in rabbits (fold of prolongation,x ±s)Group Dose (mg/kg) n Administration 5 min 15 min Physiological saline - 8 - - Bivalirudin 6.0 8 2.4±0.3 1.4±0.3 Enoxaparin 200 7 2.2±0.5 1.8±0.3 Polypeptide 2, low dose 3.0 6 1.2±0.2 1.0±0.1 Polypeptide 2, medium dose 6.0 8 2.1±0.6 1.5±0.4 Polypeptide 2, high dose 12.0 8 2.3±0.6 1.6±0.5 - The results are shown in
Figure 14 , Table 20 and Table 21.Polypeptide 2 in each dose group can prolong the PT in rabbits to different extents, and the prolongation of PT was gradually weakened over time within 15 min. - After administration for 5 min, compared with the physiological saline group, there was a significant statistic difference for the medium dose group of
polypeptide 2 in 6.0 mg/kg and the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.05); and after administration for 15 min, compared with the physiological saline group, there was a significant statistic difference for the medium dose group ofpolypeptide 2 in 6.0 mg/kg and the high dose group ofpolypeptide 2 in 12.0 mg/kg (P<0.05).Table 20. Effect of single intravenous administration of polypeptide 2 on PT in rabbits (S, x±Sc)Group Dose (mg/kg) n Before administration Administration for 5 min Administration for 15 min Physiological saline - 8 6.2±0.2 6.0±1.1 5.8±0.7 Bivalirudin 6.0 8 6.4±0.2 18.8±1.1 * 10.2±0.7* Enoxaparin 200 7 5.8±0.2 6.7±1.1 # 6.7±0.8 # Polypeptide 2, low dose 3.0 6 6.0±0.3 8.9±1.2# 7.0±0.8 Polypeptide 2, medium dose 6.0 8 6.3±0.2 12.9±1.1*#¥ 8.9±0.7* Polypeptide 2, high dose 12.0 8 6.5±0.2 19.2±1.1*¥& 12.5±0.7*¥&@ Table 21. Effect of single intravenous administration of polypeptide 2 on PT in rabbits (fold of prolongation,x ±s)Group Dose (mg/kg) n Administration 5 min 15 min Physiological saline - 8 - - Bivalirudin 6.0 8 3.0±0.5 1.6±0.2 Enoxaparin 200 7 1.2±0.1 1.2±0.1 Polypeptide 2, low dose 3.0 6 1.5±0.4 1.2±0.2 Polypeptide 2, medium dose 6.0 8 2.0±0.4 1.4±0.3 Polypeptide 2, high dose 12.0 8 3.0±0.8 2.0±0.6 - The results are shown in Table 22. Administration for 5 min and 15 min in each dose group of
polypeptide 2 can prolong TT in rabbits, which is longer than the detection limit by 180 seconds.Table 22. Effect of single intravenous administration of polypeptide 2 on TT in rabbits (S, x±Sc)Group Dose (mg/kg) n Before administration Administration for 5 min Administration for 15 min Physiological saline - 8 21.2±0.8 20.3±0.8 19.1±0.7 Bivalirudin 6.0 8 22.4±5.2 >180s > 180s Enoxaparin 200 7 20.7±4.2 >180s > 180s Polypeptide 2, low dose 3.0 6 21.0±2.6 >180s > 180s Polypeptide 2, medium dose 6.0 8 22.3±1.9 >180s > 180s Polypeptide 2, high dose 12.0 8 21.8±6.4 >180s >180s - The results are shown in
Figure 15 , Table 23 and Table 24.Polypeptide 2 in each dose group can prolong the ACT in rabbits to different extents, and the prolongation of ACT was gradually weakened over time within 15 min. - After administration for 5 min, compared with the physiological saline group, there was a significant statistic difference for the high dose group of
polypeptide 2 in 12.0 mg/kg (P<0.05). - After administration for 15 min, compared with the physiological saline group, there was a significant statistic difference for the low dose group in 3.0 mg/kg, the medium dose group in 6.0 mg/kg and the high dose group in 12.0 mg/kg of polypeptide 2 (P<0.05).
Table 23. Effect of single intravenous administration of polypeptide 2 on ACT in rabbits (s, x±Sc )Group Dose (mg/kg) n Before administration Administration for 5 min Administration for 15 min Physiological saline - 8 240.0±24.0 226.9±35.3 208.1±24.1 Bivalirudin 6.0 8 305.6±24.0 443.8±35.3* 375.0±24.1* Enoxaparin 200 7 285.0±25.6 915.0±37.7*# 610.7±25.7* # Polypeptide 2, low dose 3.0 6 357.5±27.7 352.5±40.7¥ 337.5±27.8*¥ Polypeptide 2, medium dose 6.0 8 232.5±24.0 356.3±35.3¥ 324.4±24.1*¥ Polypeptide 2, high dose 12.0 8 315.0±24.0 505.6±35.3*¥&@ 418.1±24.1*¥ Compared with the physiological saline group, *P<0.05; compared with the bivalirudin group, #P<0.05; compared with the enoxaparin group, ¥ P<0.05; compared with the low dose group of polypeptide 2, &P<0.05; compared with the medium dose group ofpolypeptide 2, @ P<0.05Table 24. Effect of single intravenous administration of polypeptide 2 on ACT in rabbits (fold of prolongation,x ±s)Group Dose (mg/kg) n After administration 5 min 15 min Physiological saline - - - - Bivalirudin 6.0 8 1.5±0.3 1.3±0.4 Enoxaparin 200 7 3.4±1.1 2.2±0.7 Polypeptide 2, low dose 3.0 6 1.0±0.2 1.0±0.1 Polypeptide 2, medium dose 6.0 8 1.7±0.7 1.6±0.9 Polypeptide 2, high dose 12.0 8 1.7±0.6 1.4±0.3 - The single intravenous administration of
polypeptide 2 can inhibit FeCl3-induced femoral arterial thrombosis in rabbits and dose-dependently inhibit femoral arterial and venous bypass thrombosis in rabbits, in which the antithrombotic effect in the medium and high doe groups thereof is superior to that in the bivalirudin group; as well aspolypeptide 2 can inhibit platelet aggregation in rabbits in a dose-dependent manner, affect the blood coagulation function in rabbits and prolong APTT, PT, TT and ACT. - This test example is used to demonstrate the protective effect of
polypeptide 2 on progressive ischemic stroke. - 1. Experimental animals: 60 healthy adult male SD rats, with body weight of 250 g to 300 g, purchased from Animal Center of Xi'an Jiaotong University Medical College. Animal production license number: SCXK (shaanxi) 2012-003.
- 2. Samples to be tested:
polypeptide 2 having a peptide content of 97.21%; control drug: enoxaparin injection, produced by Sanofi (Beijing) Pharmaceutical Co., Ltd., Lot number: 4SH69. -
- 3.1 Formulation of solution: polypeptide 2: a stock solution of 2 mg/ml was formulated prior to use.
- 3.2 Grouping and administration: At 15 min after the mold was established, administration was started by jugular vein intubation, with the first dose and the maintenance dose for 60 min, in which the administration group was administered with
polypeptide 2 at a dose of 0.25 mg/kg+0.75 mg/kg/h, while the model group was administered with physiological saline. - 3.3 Experimental operation: Suture method (common carotid artery insertion method): the skin on the neck was cut open from a median incision thereon, and the common, external and internal carotid arteries were isolated therefrom. The common carotid artery was ligated at the heart-proximal end and the external carotid artery was ligated at the distal end. The distal end of the internal carotid artery was temporarily occluded with a small vascular clamp, and at the bifurcation of the common, external and internal carotid arteries, a thread for ligature was reserved. A small opening was cut with an eye scissor on the common carotid artery which was close to the internal carotid artery, to allow a certain degree of bending of the MCAO thread, which inserted into the internal carotid artery along the common carotid artery. During the thread insertion, the thread bended towards the direction of the operator, which was slowly pushed forward about 18 mm (from the bifurcation of the arteries), and terminated when a resistance was felt. The reserved thread was ligated at the bifurcation to fix the thread. At 15 min after the mold was established, the fist dose was administered followed by maintenance dose for 60 min, and after the administration was finished, the wound in the neck was sutured in a conventional manner.
-
- 4.1 Neurobehavioral scores: Rats in both the groups were evaluated in terms of their neurobehavioral scores at 4, 8, and 24 hours after the surgery, with a Longa five-point quartering method as the standard: 0 point: no neurological defect; 1 point: adduction and failure to full extension of forelimbs on contralateral side when tail lifting; 2 points: rotation to the contralateral side; 3 points: toppling and falling to the contralateral side when walking; 4 points: failure to walk or coma. Cases with 1 to 4 points were classified as valid models.
- 4.2 observing infarct lesions and infarct volume by TTC staining: At 24 hours after the surgery, the animals were sacrificed and the brain was taken for TTC staining. The infarct volume was calculated by using a mapping software.
- 4.3 Cerebral index, cerebral water content: The rats in each group were rapidly decapitated 24 hours after the surgery and model establishment, and the whole brain was rapidly peeled off, which was then weighed for wet weight and used to calculate the brain index: Brain index = Brain wet weight/Body weight * 100%
- The test results in Tables 25 and 26 show that,
polypeptide 2 at the doses of 0.5+1.25 and 1.0+2.5 (mg/kg+mg/kg/h) reduced the cerebral infarct volume from (23.41+10.08)% to (11.12±6.56)% and (8.01±6.66)% 24 hours after the surgery, respectively; and the neurobehavioral injury was also improved, indicating the protective effect on the experimental cerebral infarction.Table 25. Effect of polypeptide 2 on neurological behaviors (x ± s)Group Dose (mg/kg+mg/kg/h) n 4h 8h 24h Sham operation group - 5 0 0 0 Model group - 19 2.32±0.75 2.37±0.83 2.50±0.99 Enoxaparin group 90U/kg+ 120U/kg/ h 8 0.63±0.74** 0.88±0.64** 1.38+0.74* Polypeptide 2group 10.5+1.25 7 1.00±0.58** 1.00±0.58** 1.00±0.58** Polypeptide 2group 21.0+2.5 7 0.86±1.07** 0.86±0.90** 1.14±0.69** Compared with the model group, *P<0.05, **P<0.01 Table 26. Effect of polypeptide 2 on cerebral infarct volume and cerebral index (x±s)Group Dose (mg/kg+mg/kg/h) n Cerebral infarct volume ratio (%) Cerebral index (%) Sham operation group - 5 0±0 0.6175:1:0.0511** Model group - 19 23.41±10.08 0.7167±0.0555 Enoxaparin group 90U/kg+ 120U/kg/ h 8 10.22±5.38** 0.6819±0.0356 Polypeptide 2 group 10.5+1.25 7 11.12±6.56** 0.6648±0.0374* Polypeptide 2group 21.0+2.5 7 8.01:1:6.66** 0.6830±0.0322 Compared with the model group, *P<0.05, **P<0.01 - This test example is used to demonstrate the protective effect of
polypeptide 2 on thrombin-induced pulmonary embolism in mice. - 1. Experimental animals: Kunming mice, male, 6 to 8 weeks old, 20 g to 25 g, provided by experimental animal center of Xi'an Jiaotong University. Animal production license number SCXK (Shaanxi) 2012-003.
-
- 2.1 Thrombin: sigma Company, Lot number T4648, derived from bovine serum, specification: 1000 U/bottle.
- 2.2 Enoxaparin injection: 0.4ml: 4000AxalU, Sanofi (Beijing) Pharmaceutical Co., Ltd., Subpackaging Approval Number: State Medicine Approval No: J20090094.
- 2.3
Polypeptide 2, which was obtained by entrusting Jill Biochemical (Shanghai) Co., Ltd., Lot number P131029-ML360794, having a peptide content of 97.21%. - BC-2800Vet Mindray automatic blood cell analyzer, Shenzhen Mindray Biomedical Electronics Co., Ltd.
- Mice were randomly divided into 7 groups with 10 mice per group, in which
group 1 was physiological saline group,group 2 was model control group,group 3 was positive control group of enoxaparin 0.5 mg/kg,group 4 was positive control group ofbivalirudin 8 mg/kg,group 5 was low dose group ofpolypeptide 2 at 2.5 mg/kg,group 6 was medium dose group ofpolypeptide 2 at 5.0 mg/kg, andgroup 7 was high dose group ofpolypeptide 2 at 10.0 mg/kg. Except that physiological saline group and model control group were subjected to tail intravenous injection of 200 µl physiological saline, the other groups were given according to the doses, respectively. After 2 min, the mice in physiological saline group were administered with 100 µl physiological saline through tail intravenous injection and the other groups were each administered with 100 µl thrombin based on 1500 u/kg (80% to 90% of the lethal dose) through tail intravenous injection. The mice were observed after the administration for their death within 15 min. Mice those did not die within 15 min were subjected to the treatments as follows. - (1) Recording mortality rate: the death status of mice with acute pulmonary embolism mice within 15 min was recorded and the survival time was recorded, to calculate the mortality rate;
- (2) Determining lung coefficient: immediately after death, the bronchial and adipose tissues were dissected away from the lung tissue, and the lung tissue was washed with distilled water, and weighed for the lung weight after soaking up the water on the surface of the lung with a filter paper. The lung was taken out and weighed, to calculate the lung coefficient. Lung coefficient = Lung weight/Body weight × 100%;
- (3) Determining the number of platelets: for the mice that did not die within 15 min, blood was taken from eyes, and measured for its number of platelets after EDTA anticoagulation. The lung was immediately dissected and taken out and weighed to determine the lung coefficient.
- In the LPS model group, 12 of 13 mice died with a mortality rate of 85%, which had a very significant difference from that of the physiological saline group (P<0.01). In the groups of enoxaparin 0.5 mg/kg,
bivalirudin 8 mg/kg, andpolypeptide 2 at a high dose 10.0 mg/kg, 1 of 10 mice died with a mortality rate of 10%, which have a very significant difference from that of the model group, respectively (P<0.01). In the medium dose group ofpolypeptide 2 at 5.0 mg/kg, 3 of 10 mice died with a mortality rate of 30%, which had a very significant difference from that of the model group (P<0.01). There was no significant difference in mortality between both the groups ofpolypeptide 2 and enoxaparin 0.5 mg/kg orbivalirudin 8 mg/kg, respectively (P>0.05). - In the low dose group of
polypeptide 2 at 2.5 mg/kg, 6 of 10 mice died with a mortality rate of 60%, which has no significant difference compared with that of the model group (P>0.05), had a significant difference compared with that of enoxaparin 250 U/kg andbivalirudin 8 mg/kg (P<0.01), and had a significant difference compared with that in groups ofpolypeptide 2 at a medium dose 5.0 mg/kg and at a high dose 10.0 mg/kg (P<0.05). For the mice in the model group, the lung coefficient significantly increased, which had a very significant difference (P<0.01) compared with the physiological saline group; the lung coefficient in thebivalirudin 8 mg/kg group decreased, which had a significant difference (P<0.05) compared with the model group; and the lung coefficient of mice in the high dose group ofpolypeptide 2 at 10.0 mg/kg group decreased, which had a very significant difference compared with the model group (P<0.01). The results are shown in Table 27 andFigure 16 , indicating thatpolypeptide 2 has protective effect on thrombin-induced pulmonary embolism in mice.Table 27. Effect of polypeptide 2 on thrombin-induced pulmonary embolism in miceGroup Dose (mg/kg) n Mortality rate (%) Lung coefficient (g/100g) Number of platelets (×109) Blank control group - 10 0** 0.82 ±0.12** 1069.4±407.01 Model group - 13 85 1.22 ±0.26 65,45±5.1 Enoxaparin group 250 IU/ kg 10 10**## 1.02 ±0.33 459.83±49.66 Bivalirudin group 8.0 10 10**## 0.99 ±0.07* 411.89 ±175.52 Polypeptide 2, high dose group 10.0 10 10**# 0.83±0.14** 529.57 ±104.28 Polypeptide 2, medium dose group 5.0 10 30**# 1.08 ±0.27 207.83±33.09 Polypeptide 2, low dose group 2.5 10 60 0.94 ±0.16* 165.33±20.2 Compared with the model group, *P<0.05, **P<0.01; compared with the low dose group of polypeptide 2: #P<0.05, ##P<0.01. - While the invention has been described in detail by way of the general description and the above specific embodiments, it will be apparent for those skilled in the art that certain modifications or improvements may be made thereto on the basis of the invention. Therefore, these modifications or improvements made without departing from the spirit of the present disclosure all fall within the protection scope of the present invention.
- The multi-target antagonistic compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism of the invention has direct, reversible and specific anti-thrombin function and also has function of inhibiting the GPIIb/IIIa receptors, which can achieve the anticoagulant and antithrombotic effect at a low dose. At the same time, the bleeding risk is reduced, and problems such as dose matching, bleeding, coordination caused by drug combination are avoided.
Claims (22)
- A multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism, said compound having a structure as shown in Formula (1):
A-L-B-L'-C Formula (1)
wherein A and B are thrombin binding sites, C is a platelet GPIIb/IIIa receptor binding site, L is a first linker, and L' is a second linker. - The compound according to claim 1, wherein L' has a structure as shown in Formula (2):
((Gly)n1-(Ser)n2)n3 Formula (2)
wherein n1 is 1, 2, 3 or 4; n2 is 0 or 1; and n3 is 0, 1, 2 or 3. - The compound according to claim 1, wherein L' has a structure as shown in Formula (3):
(Glu-Ala-Ala-Ala-Lys)n1 Formula (3)
wherein n1 is 0, 1, 2 or 3. - The compound according to claim 1, wherein L' has a structure as shown in Formula (4):
(Arg-Val-Leu-Ala-Glu-Ala)n1 Formula (4)
wherein n1 is 0, 1, 2 or 3. - The compound according to any one of claims 1 to 4, wherein A has a structure as shown in Formula (5):
A1-A2-A3-A4 Formula (5)
wherein A1 is D-Phe; A2 is Pro or Pip; A3 is Arg, Lys, Orn or Har; and A4 is Pro, D-Pro or Ser. - The compound according to claim 5, wherein B has a structure as shown in Formula (6):
B1-B2-B3-B4-B5 Formula (6)
whereinB1 is a dipeptide consisting of any two acidic amino acids;B2 is Val, Leu, Ile, Nle or Phe;B3 is Hyp, Ser, Pro or an N-methyl amino acid;B4 is a dipeptide consisting of any two acidic amino acids; andB5 is an amino acid selected from the group consisting of Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro, or B5 is a dipeptide comprising at least one amino acid selected from Tyr, Trp, Phe, Leu, Nle, Ile, Val, Cha and Pro. - The compound according to any one of claims 1 to 4 and 6, wherein C has a structure as shown in Formula (7):
Cys-Har-C1-Asp-Trp-Pro-C2 Formula (7)
wherein C1 is Gly or Ser; C2 is Cys or a structure obtained by replacing -OH in Cys with -NH2; and a disulfide bond is formed between two mercapto groups in the Formula (7). - The compound according to claim 7, wherein L has a structure as shown in Formula (8):
L1-L2-L3-L4-Gly-Asp-L5 Formula (8)
wherein L1 is Gly, Ala, Val or Gly-Gly; L2 is Gly or Cys; L3 is Gly, Gly-Gly, Gly-Gly-Gly or a dextrorotatory amino acid; L4 is Asn or Gln; L5 is one selected from Phe, Tyr, a derivative in which a benzene ring of Phe is substituted, and a derivative in which a benzene ring of Tyr is substituted. - The compound according to claim 8, wherein A-L-B is selected from one of polypeptide sequences shown in SEQ ID No. 1 to SEQ ID No. 3.
- The compound according to any one of claims 1 to 4, 6, 8 and 9, wherein said compound has a structure as shown in Formula (9):
X-A-L-B-L'-C-Y Formula (9)
wherein X is one selected from hydrogen, one or two C1-C6 alkyl, one or two C2-C10 acyl, benzyloxycarbonyl and tert-butoxycarbonyl; Y is one selected from OH, C1-C6 alkoxy, an amino, and an amino substituted with one or two C1-C4 alkyl. - The compound according to claim 10, wherein said compound comprises a polypeptide sequence of polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- The compound according to claim 11, wherein said compound is one selected from polypeptide structures shown in SEQ ID No.4 to SEQ ID No.7.
- A salt of a compound according to any one of claims 1 to 12.
- The salt of a compound according to claim 13, wherein said salt is an acetate salt of the compound or a trifluoroacetate salt of the compound.
- A method for preparing a compound according to any one of claims 1 to 12, wherein said method comprises the steps of:(1) sequentially connecting protected amino acids or fragments starting from carboxyl terminal according to polypeptide sequence using a solid phase synthesis method, to obtain a polypeptide-Wang resin in which side chains of amino acids are all protected;(2) subjecting the polypeptide-Wang resin in which side chains of amino acids are all protected to acid hydrolysis with an acid hydrolyzing agent to obtain a crude linear polypeptide; and(3) cyclizing the crude linear polypeptide to form a disulfide bond and then purifying with high-pressure preparative liquid chromatography, to obtain a polypeptide sequence.
- A pharmaceutical composition, wherein said pharmaceutical composition comprises a compound according to any one of claims 1 to 12 or a salt according to any one of claims 13 and 14 as an active ingredient.
- The pharmaceutical composition according to claim 16, wherein the dosage form of said pharmaceutical composition is an injection, a tablet, a capsule, a pill, a powder, a granule, a suspension or an emulsion.
- Use of a compound according to claims 1 to 12 or a salt according to claims 13 to 14 in the manufacture of a medicament for prevention and treatment of peripheral arterial thrombosis, arterial and venous bypass thrombosis.
- Use of a compound according to claims 1 to 12 or a salt according to claims 13 to 14 in the manufacture of a medicament for treatment of thrombosis formed in acute coronary syndromes, percutaneous coronary intervention, or therapy with a coronary stent in PCI.
- Use of a compound according to claims 1 to 12 or a salt according to claims 13 to 14 in the manufacture of a medicament for prevention and treatment of progressive ischemic stroke.
- Use of a compound according to claims 1 to 12 or a salt according to claims 13 to 14 in the manufacture of a medicament for prevention and treatment of acute pulmonary embolism.
- Use of a compound according to claims 1 to 12 or a salt according to claims 13 to 14 in the manufacture of a medicament for prevention and treatment of thrombosis in organ and tissue transplantation.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/086173 WO2017020282A1 (en) | 2015-08-05 | 2015-08-05 | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3333177A1 true EP3333177A1 (en) | 2018-06-13 |
EP3333177A4 EP3333177A4 (en) | 2018-12-26 |
EP3333177B1 EP3333177B1 (en) | 2021-07-14 |
Family
ID=57942316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15900056.1A Active EP3333177B1 (en) | 2015-08-05 | 2015-08-05 | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof |
Country Status (6)
Country | Link |
---|---|
US (1) | US11643439B2 (en) |
EP (1) | EP3333177B1 (en) |
JP (1) | JP6530564B2 (en) |
CN (4) | CN113201049B (en) |
ES (1) | ES2886576T3 (en) |
WO (1) | WO2017020282A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3401356A1 (en) * | 2017-05-12 | 2018-11-14 | Solvay SA | Fluoropolymer hybrid composite |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5318899A (en) | 1989-06-16 | 1994-06-07 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5196404B1 (en) * | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
GB9023149D0 (en) * | 1990-10-24 | 1990-12-05 | British Bio Technology | Proteins and nucleic acids |
US7771727B2 (en) | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
IES20030298A2 (en) * | 2002-04-23 | 2003-10-29 | R Stephen Porter | Inhibition of platelet aggregation |
US20070253966A1 (en) | 2003-06-12 | 2007-11-01 | Eli Lilly And Company | Fusion Proteins |
US20090054319A1 (en) | 2005-03-17 | 2009-02-26 | Microbia, Inc. | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders |
CN1810836A (en) * | 2006-02-17 | 2006-08-02 | 北京师范大学 | Human proinsulin-KGD chimeric peptide as new recombinat antithrombotic with thrombocyte GP-IIb-IIIa receptor specificity |
CN101284877A (en) | 2008-05-30 | 2008-10-15 | 重庆大学 | Recombinant target fusion protein of antithrombin activity and anti-platelet aggregation and preparation method |
US7803762B1 (en) * | 2009-08-20 | 2010-09-28 | The Medicines Company | Ready-to-use bivalirudin compositions |
WO2012050930A2 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc | Engineered polypeptides having enhanced duration of action |
CN102241734B (en) * | 2011-04-15 | 2014-04-02 | 广东医学院 | Anticoagulation polypeptide and application thereof |
CN102241735B (en) * | 2011-06-23 | 2014-01-22 | 陕西麦科奥特科技有限公司 | Polypeptide used for prevention and treatment of acute coronary syndrome and anticoagulation antithrombotic therapy and application thereof |
CN102702325B (en) * | 2012-06-19 | 2015-09-23 | 深圳翰宇药业股份有限公司 | A kind of preparation method of anticoagulant peptides |
CN107759662B (en) * | 2013-08-28 | 2020-10-30 | 北京赛而生物药业有限公司 | Anticoagulant compound, preparation method and application thereof, and pharmaceutical composition containing anticoagulant compound |
CN104193807B (en) * | 2014-09-28 | 2016-06-15 | 广州贝奥吉因生物科技有限公司 | Thrombin suppresses polypeptide and preparation method thereof, application |
CN104193809B (en) * | 2014-09-28 | 2016-08-17 | 顾玉奎 | A kind of thrombin suppression and preparation method thereof, application |
-
2015
- 2015-08-05 CN CN202110662996.2A patent/CN113201049B/en active Active
- 2015-08-05 EP EP15900056.1A patent/EP3333177B1/en active Active
- 2015-08-05 US US15/749,622 patent/US11643439B2/en active Active
- 2015-08-05 WO PCT/CN2015/086173 patent/WO2017020282A1/en active Application Filing
- 2015-08-05 CN CN201580082185.8A patent/CN108137653B/en active Active
- 2015-08-05 JP JP2018526284A patent/JP6530564B2/en active Active
- 2015-08-05 CN CN202110661682.0A patent/CN113201048B/en active Active
- 2015-08-05 CN CN202110662995.8A patent/CN113773369B/en active Active
- 2015-08-05 ES ES15900056T patent/ES2886576T3/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3333177B1 (en) | 2021-07-14 |
CN113773369B (en) | 2022-11-08 |
CN108137653B (en) | 2021-07-13 |
CN113201049B (en) | 2022-10-04 |
US11643439B2 (en) | 2023-05-09 |
CN113201049A (en) | 2021-08-03 |
JP2018525442A (en) | 2018-09-06 |
ES2886576T3 (en) | 2021-12-20 |
EP3333177A4 (en) | 2018-12-26 |
CN113201048A (en) | 2021-08-03 |
CN113773369A (en) | 2021-12-10 |
CN113201048B (en) | 2022-10-04 |
JP6530564B2 (en) | 2019-06-12 |
CN108137653A (en) | 2018-06-08 |
US20180305409A1 (en) | 2018-10-25 |
WO2017020282A1 (en) | 2017-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107075574A (en) | Hepcidin and Mini-hepcidin analog and application thereof | |
CN103830719A (en) | Methods for performing coronary artery bypass graft procedure | |
BRPI0721259A2 (en) | compound, pharmaceutical composition, use of compound, and process for the manufacture of compound | |
JP5208135B2 (en) | Recombinant leukocyte inhibitory factor and hirugen chimeric protein and drug composition thereof | |
US5498601A (en) | Platelet aggregation-inhibiting peptides | |
EP3453716A1 (en) | Polyethylene glycol-modified angiogenesis inhibitor hm-1 and application thereof | |
CN107629114B (en) | Polypeptide, derivative thereof and application thereof in preparation of anti-pulmonary fibrosis drugs | |
EP3333177B1 (en) | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof | |
CN115803338A (en) | C-type natriuretic peptide and method for treating acute lung injury | |
EP0721468B1 (en) | Platelet aggregation inhibitory peptides | |
WO2019006692A1 (en) | Compound for treating, ameliorating, or preventing disease related to nervous system and use thereof | |
CA2737953A1 (en) | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
CN103145800B (en) | Centipede zymolyte anti-thrombus polypeptide | |
EP0333517A2 (en) | Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor | |
CN109336963A (en) | Novel erythropoietin simulates peptide dimer and its preparation method and application | |
WO2019037482A1 (en) | Polypeptides having thrombolytic activity | |
JP2000511511A (en) | Biologically active protein for tumor growth inhibition and capillary growth, collagen fragment HF-COLL-18 / 514cf | |
WO1995001371A1 (en) | Novel peptide and antiplatelet aggregation containing the same | |
CN115093457A (en) | Anticoagulant polypeptide KT12 and application thereof | |
JPH10182479A (en) | Medicine comprising polypeptide derivatives | |
WO2011120040A2 (en) | Thrombin inhibiting compositions | |
CN101974076A (en) | Cyclic peptide for inhibiting cell proliferation and blood vessel hyperplasia induced by basic fibroblast growth factors | |
JPH06157588A (en) | Cell adhesion active new peptide derivative | |
JPH0797397A (en) | New peptide and platelet aggregation inhibitor containing the same | |
JPH069687A (en) | New peptide and blood platelet coagulation inhibitor using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180221 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20181128 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 9/10 20060101ALI20181123BHEP Ipc: C07K 9/00 20060101AFI20181123BHEP Ipc: A61P 7/02 20060101ALI20181123BHEP Ipc: A61K 38/16 20060101ALI20181123BHEP Ipc: C07K 14/00 20060101ALN20181123BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20191213 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/16 20060101ALI20200622BHEP Ipc: A61P 9/10 20060101ALI20200622BHEP Ipc: A61P 7/02 20060101ALI20200622BHEP Ipc: C07K 9/00 20060101AFI20200622BHEP Ipc: C07K 14/00 20060101ALN20200622BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/00 20060101ALN20210122BHEP Ipc: A61K 38/16 20060101ALI20210122BHEP Ipc: A61P 7/02 20060101ALI20210122BHEP Ipc: C07K 9/00 20060101AFI20210122BHEP Ipc: A61P 9/10 20060101ALI20210122BHEP |
|
INTG | Intention to grant announced |
Effective date: 20210303 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015071395 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1410580 Country of ref document: AT Kind code of ref document: T Effective date: 20210815 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210714 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1410580 Country of ref document: AT Kind code of ref document: T Effective date: 20210714 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2886576 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211014 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211115 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211015 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015071395 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210805 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 |
|
26N | No opposition filed |
Effective date: 20220419 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210805 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20150805 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230822 Year of fee payment: 9 Ref country code: GB Payment date: 20230828 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230825 Year of fee payment: 9 Ref country code: DE Payment date: 20230829 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231020 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 |